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The vasculature infuses nearly every tissue with oxygen and nutrients. It 
facilitates the transport of cells and chemical messages throughout the body and 
maintains proper fluid balance in the individual tissues. During angiogenesis and 
inflammation, vessels that compose the vasculature display enhanced permeability. This 
leak is regulated by the monolayer of endothelial cells that line each vessel. This thesis 
aims to further describe the molecular mechanisms within endothelial cells that control 
vascular leak. I present our research identifying a molecular signaling axis that controls 
vascular leak induced by inflammatory cues through the small GTPase ADP-
ribosylation factor 6 (ARF6). We show that blockade of ARF6 enhances endothelial 
barrier function, reduces vascular leak, and prevents inflammatory pathology.  
We identify a signaling axis composed of Myeloid Differentiation Factor 88 
(MYD88), ARF-Nucleotide Binding Site Opener (ARNO), and ARF6 in endothelial 
cells that is used by the inflammatory cytokine, interlukin-1β (IL-1β), to dissociate cell 
junctions and enhance vascular leak. We determined that IL-1β enhances permeability 
rapidly, independently of gene-expression changes, and in a manner dependent on 
ARF6 activation. We showed that ARF6 activation induced the dissociation of the cell 
junction protein vascular endothelial cadherin (VE-Cadherin) and when ARF6 was 
blocked, VE-Cadherin dissociation was prevented and vascular permeability was
    iv 
reduced. Inhibiting this signaling axis in mice with a small molecule inhibitor reduced 
vascular leak and inflammatory pathologies associated with arthritis. 
MYD88 is a crucial adapter protein for many inflammatory pathways, including 
the Toll-like-receptors (TLRs). TLRs are the primary receptors that detect pathogens by 
recognizing danger-associated molecular patterns (DAMPs) such as bacterial 
lipopolysaccharaides (LPS) and initiating an inflammatory cascade. We determined that 
the MYD88-ARNO-ARF6 cascade is also responsible for vascular leak induced by 
LPS. We characterized the peptide MyrARF6 2-13 as an inhibitor of ARF6 activation 
and showed that peptide treatment is sufficient to reduce vascular leak and enhance 
survival of mice in experimental sepsis. 
We suggest that ARF6 controls inflammatory pathology independent of 
inflammatory factors such as cytokines. Such observations suggest that vascular leak 
itself could be a key driver of inflammatory pathology and may pave the way for the 
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“A discovery in science, or a new theory, even when it appears most unitary and most 
all-embracing, deals with some immediate element of novelty or paradox within the 
framework of far vaster, unanalyzed, unarticulated reserves of knowledge, experience, 
faith, and presupposition. Our progress is narrow; it takes a vast world unchallenged 
and for granted. This is one reason why, however great the novelty or scope of new 
discovery, we neither can, nor need, rebuild the house of the mind very rapidly. This is 
one reason why science, for all its revolutions, is conservative. This is why we will have 
to accept the fact that no one of us really will ever know very much. This is why we 
shall have to find comfort in the fact that, taken together, we know more and more.”   
 




“Science never solves a problem without creating ten more.” 
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        In mammals, the vasculature is an essential network composed of blood vessels 
that infuse nearly every tissue. This ubiquitous placement throughout the body makes it at 
least tangentially involved in almost all described pathology. The vasculature is 
responsible for the transport of oxygen, nutrients, and leukocytes at proper levels into the 
appropriate tissues at the appropriate times. Lining the vasculature are endothelial cells 
that maintain barrier function to control the passage of the transported constituents while 
maintaining proper fluid balance in the tissues. In order to regulate barrier function, 
endothelial cells modulate transcytosis, fenestrae, and cell-cell junction molecules such as 
adherens and tight junctions. Vascular barrier function is directly responsible for 
controlling swelling, one of the five cardinal signs of inflammation. The endothelial 
signaling mechanisms by which this permeability occurs and the contribution of vascular 
permeability to disease pathology are poorly described. 
Vascular leak has been observed in nearly all described inflammatory pathologies; 
key examples include infection, trauma, cancer, epilepsy, and autoimmune diseases such 
as arthritis and multiple sclerosis (MS)1. Vascular leak is often localized to the site of 
infection and immune response. For example, in conditions such as arthritis or MS, the 
vascular leak is limited to either the problematic joints or isolated areas of the central
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nervous system. The same is true for epilepsy and localized infections where vascular 
leak is limited to the epileptic foci or the site of infection. In instances such as severe flu, 
the vascular leak in the lungs can be so extreme that oxygen exchange with the blood is 
inhibited and the patient suffocates 2. Infections and immune responses can also become 
disseminated and induce systemic inflammatory responses, causing widespread vascular 
leak3. Conditions such as viral hemorrhagic fever and bacteremia induce such profound 
disseminated vascular leak that shock is induced from the reduced blood volume and 
tissues cannot properly transport nutrients and oxygen. Currently, the primary treatments 
for such disseminated inflammatory conditions include fluid replacement therapy, 
administration of the appropriate antibiotics, and in some cases, anti-inflammatories 1a, 4. 
However, with these treatment options, morbidity and mortality are still very high and 
novel approaches need to be developed. One potential strategy may be to directly block 
inflammatory vascular leak and prevent excess fluid from disrupting tissue and organ 
function while allowing the canonical inflammatory response to progress uninhibited. 
 
The mechanisms of vascular leak 
In order for fluid to leave the vasculature and enter the periphery, it has to cross a 
monolayer of endothelial cells. Fluid can cross the endothelial monolayer in a 
transcellular manner (directly through cells) or in a paracellular manner (around 
individual cells). Trancellularly passage occurs either through endothelial fenestrae, in 
which a single endothelial cell resembles a sieve, or through caveolae-mediated vesicular 
transport 5 (Figure 1.1).  
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Endothelial fenestrae are present only on specialized tissues where molecular 
exchange with the blood is common, such as within the endocrine system and the 
kidneys. Although many signaling mechanisms can facilitate caveolae-mediated vesicular 
transport, one of the best-documented examples is albumin-stimulated transcytosis. Free 
albumin binds to and stimulates the transmembrane receptor gp60 on the luminal side of 
the endothelial membrane, which releases activated Gαi and c-Src into the cytosol. c-Src 
is then free to phosphorylate Cav-1 and dynamin, leading to the assembly of dynamin at 
the caveolar neck and initiation of caveolar scission. This also nonspecifically captures 
unbound, fluid-phase proteins in the vesicle. The vesicle and its contents are then 
transported to the abluminal side of the cell where it fuses with the membrane and 
contents are released 5. Fluid-phase proteins are more accessible to the endocytic vesicle 
if they display a Stokes-Einstein radius of 3.6nm (about 60 kDa) or lower Figure 1.2 6. 
Fluid and molecules also exit the vasculature between endothelial cells in a 
paracellular manner. Complex networks of intercellular junctional protein linkages join 
the endothelial cells within the monolayer and help prevent leak. The two types of 
junction proteins on endothelial cells that control permeability are adherens junctions and 
tight junctions. Adherens junctions such as vascular-endothelial cadherin (VE-Cadherin) 
are stabilized by linkages to cytoskeletal backbone, initiate cell-cell contacts, and 
promote junctional maturation 7. Endothelial tight junction proteins such as the Zona 
Occludens (ZO) family and the Claudins enhance junctional stabilization on more mature 
junctions and do not assemble without the presence of VE-Cadherin 7. Endothelial cell 
contractility mediated by force generation of myosin light chain (MLC) on the actin 
fibers has also been implicated in endothelial permeability 8. However, the relationship of 
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cell contractility by MLC to actin and junction protein stabilization by actin remains 
poorly understood. 
 
The regulation of vascular leak 
Regulation of endothelial permeability through cell-cell junctions is highly 
complex and dynamic, involving both transcription-dependent and -independent 
mechanisms. For example, binding of the transcription factors Forkhead Box factor 
(FOX01) and beta-catenin to the claudin-5 promoter blocks transcription of claudin-5 
mRNA and reduces claudin-5 levels at the cell junction 9. Tyrosine phosphorylation of 
VE-Cadherin is the best-characterized mechanism of regulating VE-Cadherin presence at 
the cell junction. Kinases such as the Src, c-Src, and proline-rich tyrosine kinase 2 
(PYK2) and phosphatases like vascular endothelial protein tyrosine phosphatase (VE-
PTP) mediate the phosphorylation of VE-Cadherin depending on the permeability-
enhancing stimulant 10. In addition to the direct phosphorylation of VE-Cadherin, 
phosphorylation of the catenins that facilitate VE-Cadherin attachment to the 
cytoskeleton has also been documented to release VE-Cadherin from the cell junction. 
For example, proline-rich tyrosine kinase 2 (PYK2) phosphorylates beta-catenin and 
releases it from VE-Cadherin 11. 
Regulating the kinases and phosphates that control VE-Cadherin phosphorylation 
and leak are a vast array of endothelial receptors that respond to autocrine, exocrine, and 
paracrine signals such as growth factors, inflammatory cytokines, and many other classes 
of ligands. For example, the permeability-enhancing stimulants VEGF through VEGFR, 
a receptor tyrosine kinase, and thrombin through its G-protein coupled receptor both 
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disrupt VE-Cadherin function 12. Conversely, there are cues that enhance VE-Cadherin 
deposition at endothelial cell junctions. These include angiopoietin through its receptor 
Tie2, which prevents SRC-mediated VE-Cadherin phosphorylation 13, and Slit2 through 
the Robo4 receptor 14. Robo4-dependent endothelial stabilization is dependent on its 
ability to recruit a GTPase activating protein (GAP), G-protein-coupled receptor kinase 
interacting 1 (GIT1) to deactivate the small GTPase ADP-ribosylation factor 6 (ARF6) 15.  
The ARF-family of proteins are members of the RAS-superfamily of GTPases 
and are major components of the vesicular trafficking system. ARF6 activation is 
controlled by guanine nucleotide exchange factors (GEFs) and GTPase activating 
proteins (GAPs). GEFs such as Arf-Nucleotide binding site Opener (ARNO) facilitate 
replacement of guanosine di-phosphate with guanosine tri-phosphate onto the GTPase. 
This exchange induces a conformational change that is traditionally classified as an active 
conformation 16. GAPs such as GIT1 induce the intrinsic GTPase activating activity of 
ARF6 that initiates the removal of a phosphate from GTP inducing a deactivated state 
conformational change 17. ARF6 is typically present on the plasma membrane and 
endocytic vesicles and is an important activator of phosphatidylinositol 4-phosphate 5-
kinase-α  PI(4)P5α and PI(4,5)P2 synthesis 18. ARF6 is also necessary for internalization 
and downstream signaling cascades induced by many receptors, including epidermal 
growth factor receptor (EGFR)19, vascular endothelial growth factor receptor 2 
(VEGFR2)20, and insulin receptor complex signaling 21. A role for ARF6 in the 
regulation of vascular leak and the internalization of endothelial adherens junction 




Vascular leak is a common observation in numerous inflammatory pathologies, 
but the contribution of vascular leak to disease remains poorly described. Pro-
inflammatory stimuli such as interleukin-1β, interleukin-6, TNF-α, and bacterial 
lipopolysaccharides are all sufficient to induce endothelial permeability in both cell 
culture and live animal models. Additionally the blockade of the cytokine receptors 
results in a reduction in pathology in many inflammatory models 1e, 5, 22. For example 
blockade of IL-1β, TNF-α, and IL-6 signaling cascades in arthritis reduces pathology in 
animal models as well as human patients 1e, 23. Similar results are often observed in 
sepsis, a condition in which the vascular leak is so immense that death is precipitated 
from shock induced by the lack of blood volume 1a, 4a, 22b, 24. However, conflicting data 
and phase-III clinical trials suggest that such broad anti-inflammatory interventions still 
allow for substantial mortality and, especially when given chronically, leave individuals 
immunocompromised and susceptible to dangerous side effects such as inability to clear 
infection 4a, 25. It is possible that by further defining the signaling pathways responsible 
for the induction of vascular leak by these pro-inflammatory cues, we may uncover a 
branchpoint by which vascular leak uncouples from the other inflammatory processes. 
We may then be able to pharmacologically target these signaling pathways to reduce 




This thesis describes the identification of a novel branch to the signaling cascades 
induced by IL-1β and bacterial lipopolysaccharides (LPS) that control vascular leak. We 
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have identified an association by which MYD88, a critical scaffold protein for IL-1R and 
TLR signal transduction, which links ARNO to the receptors, leading to ARF6 activation 
and paracellular vascular leak through the internalization of VE-Cadherin. Blocking this 
cascade with inhibitors of ARF6 enhances VE-cadherin deposition at cell junctions and 
reduces vascular leak in both tissue culture assays and in live animal models. This 
blockade prevents pathology in murine collagen-induced arthritis and lethal endotoxemia 
assays without blocking inflammatory cytokine production. Collectively, these results 
implicate vascular leak as a key driver of disease pathology and it identifies 






















Figure 1.1 The three mechanisms of vascular leak. In paracellular vascular leak, 
luminal components may exit between adjacent endothelial cells through cell junctions. 
During transcellular vascular leak, (1) luminal components are endocytosed into vesicles, 
(2) the endocytic vesicle is trafficked to the ablumenal side of the endothelial cell, and (3) 
the vesicle fuses with the plasma membrane to release the vesicle contents into the 
peripheral tissues. Fluid may also pass through endothelial fenestrations present in the 




Figure 1.2. The permeability (P) of various molecules arranged by size through an 
endothelial monolayer. Signaling Mechanisms Regulating Endothelial Permeability 
Dolly Mehta, Asrar B. Malik Physiological Reviews Published 1 January 2006, Vol. 86,. 
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CHAPTER 2 
 
INTERLEUKIN RECEPTOR ACTIVATES A MYD88-ARNO-ARF6 CASCADE TO 
DISRUPT VASCULAR STABILITY 
 
The following chapter was reprinted with permission from Macmillian Publishers 
Limited. My co-authors were Weiquan Zhu, Nyall London, Christopher Gibson, 
Zongzhong Tong, Lise K. Sorensen, Dallas S. Shi, Jinping Guo, Matthew C.P. Smith, 
Allie H. Grossmann, Kirk R. Thomas, and Dean Y. Li. This article was originally 
published in Nature, 2012 Dec; 492:252-255. Here we identify the MYD88-











cascade to disrupt vascular stability
Weiquan Zhu1,2*, Nyall R. London1,2,3*, Christopher C. Gibson2,4*, Chadwick T. Davis2,5, Zongzhong Tong6, Lise K. Sorensen2,
Dallas S. Shi2,5, Jinping Guo1,2,7, Matthew C. P. Smith1,2,3, Allie H. Grossmann2,8, Kirk R. Thomas1,2 & Dean Y. Li1,2,3,9,10
The innate immune response is essential for combating infectious
disease. Macrophages and other cells respond to infection by
releasing cytokines, such as interleukin-1b (IL-1b), which in turn
activate a well-described, myeloid-differentiation factor 88
(MYD88)-mediated, nuclear factor-kB (NF-kB)-dependent tran-
scriptional pathway that results in inflammatory-cell activation
and recruitment1–4. Endothelial cells, which usually serve as a
barrier to the movement of inflammatory cells out of the blood
and into tissue, are also critical mediators of the inflammatory
response5,6. Paradoxically, the cytokines vital to a successful immune
defence also have disruptive effects on endothelial cell–cell inter-
actions and can trigger degradation of barrier function and dis-
sociation of tissue architecture7–9. The mechanism of this barrier
dissolution and its relationship to the canonical NF-kB pathway
remain poorly defined. Here we show that the direct, immediate
and disruptive effects of IL-1b on endothelial stability in a human
in vitro cell model are NF-kB independent and are instead the
result of signalling through the small GTPase ADP-ribosylation
factor 6 (ARF6) and its activator ARF nucleotide binding site
opener (ARNO; also known as CYTH2). Moreover, we show that
ARNO binds directly to the adaptor protein MYD88, and thus
propose MYD88–ARNO–ARF6 as a proximal IL-1b signalling
pathway distinct from that mediated by NF-kB. Finally, we show
that SecinH3, an inhibitor of ARF guanine nucleotide-exchange
factors such as ARNO, enhances vascular stability and significantly
improves outcomes in animal models of inflammatory arthritis
and acute inflammation.
A defining characteristic of the cytokine-induced inflammatory
response is the destabilization of endothelial barriers resulting in vas-
cular permeability7–9. To dissect the pathway(s) involved in this tissue
disruption, we treated cultured monolayers of human dermal micro-
vascular endothelial cells (HMVEC-d) with IL-1b, and detected an
increase in endothelial permeability within 15min (Fig. 1a). The
canonical IL-1b pathway involves ligand-stimulated activation of
interleukin-1 receptor (IL-1R), which recruits MYD88 to its cytoplas-
mic tail10. The subsequent signalling cascade through IRAK1 results in
the phosphorylation of IkB-a by the IkB kinase (IKK) complex, lead-
ing to translocation of NF-kB to the nucleus and the eventual tran-
scription of target genes that promote inflammatory-cell responses3,4
(Supplementary Fig. 1). To test the involvement of this pathway in IL-
1b-induced vascular permeability, cells were treated with the IKK
inhibitor SC-514 (ref. 11). Although SC-514 prevented IL-1b-induced
nuclear localization of NF-kB, it was unable to rescue either IL-1b-
induced permeability or disruption of vascular endothelial (VE)-
cadherin surface localization (Fig. 1b, c and Supplementary Fig. 2a–c).
We also wonderedwhether IL-1b-induced vascular permeability required
other known MYD88-mediated downstream signalling mechanisms,
including ERK1/2, p38 and JNK (also known as MAPK3/MAPK1,
MAPK14 and MAPK8, respectively)12,13. Although ERK1/2, p38 and
JNK were activated by IL-1b stimulation of endothelial cells, small-
molecule inhibitors of each of these pathways were unable to prevent
IL-1b-induced vascular permeability or IL-1b-induced disruption
of VE-cadherin cell-surface localization (Supplementary Fig. 2d–h).
Although specific NF-kB targets, such as VEGFA, COX-2 (also known
as PTGS2) and the COX-2 product prostaglandin E2 aremodulated by
IL-1b, their activation had no effect on IL-1b-induced endothelial
permeability3,14,15 (Supplementary Fig. 3a–e). Finally, treatment with
actinomycin D or cycloheximide effectively inhibited transcription or
translation, respectively, of NF-kB targets, but did not blunt IL-1b-
induced permeability (Fig. 1d and Supplementary Fig. 3f, g). These
data strongly support a role for the immediate and destabilizing effects
of IL-1b on endothelial stability through signalling pathways inde-
pendent of NF-kB, transcription and translation.
IL-1b can disrupt VE-cadherin cell-surface localization by promo-
ting endocytic internalization9. We proposed that IL-1b might use
ARF6, a known regulator of adherens protein localization16,17.
Indeed, IL-1b activated ARF6 in HMVEC-d within 1min, a response
accompanied by increased endocytosis of VE-cadherin within 5min
and an increase in monolayer permeability within 15min (Fig. 1a, e
and Supplementary Fig. 4a, b). IL-1b treatment did not affect total VE-
cadherin messenger RNA or protein levels (Supplementary Fig. 4c, d).
Adenoviral-mediated overexpression of constitutively active ARF6
(ARF6(Q67L))18 elicited a dose-dependent increase in endothelial per-
meability, as well as a disruption of VE-cadherin cell-surface locali-
zation (Fig. 1f, g and Supplementary Fig. 4e, f). A similar dose-
dependent loss of total VE-cadherin was also observed, probably
through internalization and subsequent degradation (Supplementary
Fig. 4g). Interestingly, at lower doses of adenovirus at which permea-
bility was still induced, loss of total VE-cadherin was not observed, but
a dose-dependent loss of cell-surface VE-cadherin occurred (Fig. 1f–h
and Supplementary Fig. 4g). Moreover, short interfering RNA
(siRNA) knockdown of ARF6 enhanced VE-cadherin cell-surface
localization and prevented both IL-1b-induced disruption of VE-
cadherin and IL-1b-induced endothelial permeability (Fig. 1i–k and
Supplementary Fig. 4h, i). Collectively, these data link ARF6 as a
critical regulator of VE-cadherin trafficking by controlling cell-surface
localization and the immediate and disruptive effects of IL-1b-induced
vascular permeability.
The ARF6 activation state is decreased through interaction with
GTPase-activating proteins (GAPs) and increased through interaction
with guanine nucleotide-exchange factors (GEFs). Consistent with
this, treatment of endothelial cells with the ARF-GAP inhibitor
QS11 evoked an increase in ARF6–GTP, a decrease in VE-cadherin
cell-surface localization and increased permeability (Fig. 2a–d and
1Department of Medicine, University of Utah, Salt Lake City, Utah 84112, USA. 2Program in Molecular Medicine, University of Utah, Salt Lake City, Utah 84112, USA. 3Department of Oncological Sciences,
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of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China.
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Supplementary Fig. 5a, b)19. We noted that a class of ARF-GEFs, the
cytohesins, is highly expressed in multiple types of endothelial cells
(Supplementary Fig. 5c). Accordingly, treatment of HMVEC-d with
SecinH3, a cytohesin inhibitor, significantly increased endothelial cell-
surface localization of VE-cadherin (Supplementary Fig. 5d–f)20.
Notably, SecinH3 inhibited IL-1b-induced ARF6–GTP, as well as
IL-1b-induced disruption of VE-cadherin cell-surface localization and
endothelial permeability (Fig. 2e–g and Supplementary Fig. 5g, h).
To determine which GEF might be uniquely involved, we used
siRNA to knockdown CYTH1, ARNO and CYTH3 (coding for cyto-
hesins 1, 2 and 3, respectively) and GEP100 (also known as IQSEC1)
(Supplementary Fig. 6a), and found that only siRNA targeting ARNO
completely blocked IL-1b-induced endothelial permeability and pheno-
copied the knockdown of ARF6 (Fig. 2h and Supplementary Fig. 6b).
Furthermore, ARNO siRNA inhibited IL-1b-induced ARF6–GTP
formation, IL-1b-induced disruption ofVE-cadherin cell–cell contacts
and IL-1b-induced internalization of surface VE-cadherin (Fig. 2i, j
and Supplementary Fig. 6c, g); all of these effects were rescued by the
expression of siRNA-resistant ARNO (Supplementary Fig. 6d–g). In
cells treated with ARNO siRNA, viral expression of siRNA-resistant
ARNO, but not viral expression of siRNA-resistant ARNO(E156K)
(carrying a mutation in the Sec7 domain), rescued the disruption of
IL-1b-induced ARF6–GTP formation and permeability21 (Supplemen
tary Fig. 6d, e). These data demonstrate that ARNO is a critical ARF-
GEF necessary for IL-1b-induced activation of ARF6 and subsequent
induction of vascular permeability, but does not rule out the role of
other GEF family members in similar responses in different cell types
or in response to different cytokines.
The signalling components in the NF-kB pathway downstream of
IL-1b-induced activation of IL-1R are well characterized (Supplemen-
tary Fig. 1). Although the inhibition of the NF-kB pathway at the
level of IRAK1 by siRNA did not inhibit IL-1b-induced ARF6 acti-
vation, siRNA knockdown of MYD88 inhibited both IL-1b-induced
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Figure 2 | Inhibition of ARF-GAPs and ARF-GEFs affect ARF6 activation
and VE-cadherin localization. a–d, HMVEC-d treated with QS11, showing
whole-cell lysates precipitated with GST–GGA3 and immunoblotted for
ARF6 (a), membrane fractions immunoblotted for VE-cadherin
(b), immunofluorescence for VE-cadherin (red) (c) and permeability to HRP
(d). e–g, HMVEC-d treatedwith IL-1b and SecinH3, showing immunoblotting
for ARF6 (e), immunofluorescence for VE-cadherin (f) and permeability to
HRP (g). h–j, HMVEC-d treated with anti-ARNO siRNA and stimulated with
IL-1b, showing permeability to HRP (h), GST–GGA3 precipitation and ARF6
immunoblotting (i) and immunofluorescence of VE-cadherin (j). Arrow
denotes less cell-surfaceVE-cadherin.n$ 3; error bars denote s.e.m. *P, 0.05,
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Figure 1 | Immediate effects of IL-1b are NF-kB independent and ARF6
dependent. a–d, Monolayers of HMVEC-d stimulated with IL-1b and assayed
for permeability to horseradish peroxidase (HRP) over time (a), permeability to
HRP following 2-h treatmentwith SC-514 (b), immunofluorescent localization
of VE-cadherin (c) and permeability to HRP after 30-min treatment with
actinomycin D or cycloheximide (d). e, IL-1b-stimulated HMVEC-d lysates
were precipitated with glutathione S-transferase (GST)–GGA3 and
immunoblotted forARF6. f–i, HMVEC-dmonolayers infectedwith adenovirus
(Ad) containing empty vector (null), green fluorescent protein (GFP) or
ARF6(Q67L), showingpermeability (f) andVE-cadherin localization (g) (green
denotes ARF6 expression). Membrane fractions from adenoviral-vector-
infected (h) or ARF6-siRNA-treated (i) HMVEC-d were immunoblotted for
VE-cadherin. j, k, ARF6-siRNA-treated HMVEC-d stimulated with IL-1b,
showing VE-cadherin localization (j) (arrows denote disrupted VE-cadherin
cell-surface localization) and permeability (k). A.U., arbitrary unit; DMSO,
dimethylsulphoxide; IB, immunoblot; TCL, total cell lysate. n$ 3; error
bars denote s.e.m. *P, 0.05, **P, 0.01, ***P, 0.001, ****P, 0.0001.
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IL-1b-induced signalling at the point of MYD88 (Fig. 3a–c and
Supplementary Fig. 7a, b). The proposed bifurcation was further
verified by the pharmacological uncoupling of the two pathway arms:
although SecinH3 blunted IL-1b-induced permeability, it did not
significantly inhibit IL-1b-induced NF-kB nuclear localization or
NF-kB-dependent expression or localization of cell-surface adhesion
molecules (Fig. 3d and Supplementary Fig. 7c, d). Furthermore,
SecinH3 was unable to inhibit IL-1b-induced polymorphonuclear
leukocyte rolling and adherence under shear stress on an endothelial
monolayer (Supplementary Fig. 7e). Mechanistic support for this
novel signalling arm was provided by the demonstration of an inter-
action between MYD88 and ARNO by co-immunoprecipitation in
both overexpression and endogenous settings (Fig. 3e, f). Our hypo-
thesis that ARNO is the critical GEF in IL-1b-induced permeability in
endothelial cells was further strengthened by our inability to detect an
interaction betweenMYD88 and other potentially relevantARF-GEFs
including CYTH1, CYTH3 and GEP100 (Supplementary Fig. 7f, g).
An effective therapeutic strategy to combat numerous inflammatory
conditions is to target pro-inflammatory cytokines proximal to the NF-
kB pathway. However, this strategy can result in undesired pleiotropic
effects. We wanted to know whether targeting a single arm in this
pathway—the one mediated by ARNO–ARF6—could inhibit acute or
chronic inflammation in vivo in two animal models of inflammation.
The first model we tested was rheumatoid arthritis, a disease characte-
rized by a dysregulated cytokine response causing excessive inflam-
mation and tissue damage and treated therapeutically in humans with
the anti-cytokine tumour necrosis factor receptor (TNFR)–Fc fusion
protein etanercept (Enbrel)22–25. A standard animal model of arthritis
through which a TNFR fusion approach has been proven effective is
collagen-induced arthritis (CIA)24–26. Exposure of animals to the cyto-
hesin inhibitor SecinH3 after the onset of CIA reduced vascular per-
meability in the joints, but had no effect on global cytokine levels at 24 h
after treatment initiation (Fig. 4a and Supplementary Fig. 8a, b). In
addition, a significant inhibition in the increase in arthritic index,
comparable to that achieved by treatment with Enbrel, was observed.
The arthritic index is a scoring system determined by the number of
digits or joints that are oedematous or erythematous. The significance
of our findings was verified by histologic scoring of inflammation,
pannus development, cartilage damage and bone damage (Fig. 4c,
d). A similar effect of SecinH3 was confirmed in a second model of
inflammation, the carrageenan air-pouch model. Six hours after an
inflammatory stimulus, a time at which substantial inflammation was
induced in the positive controlmice, treatment with SecinH3 decreased
exudate volume as well as leukocyte concentration in the exudates
(Supplementary Fig. 8c, d). Collectively, these data identify MYD88–
ARNO–ARF6 as a valid target for inflammatory conditions confirming
a relevant role for manipulation of this pathway in vivo to modulate


























































































































































































Figure 3 | The immediate IL-1b-induced permeability pathway diverges at
MYD88. a, IRAK1-siRNA-treated HMVEC-d, stimulated with IL-1b,
subjected to ARF6–GTP pull-down and immunoblotted for ARF6.
b, c,MYD88-siRNA-treated HMVEC-d stimulated with IL-1b, showing
permeability and ARF6 activation. d, NF-kB p65 (also known as RELA)
immunofluorescence in HMVEC-d stimulated with IL-1b and SecinH3.
Arrows denote nuclear localization. e, Cell lysates from Ad-ARNO–MYC-
infected HMVEC-d immunoprecipitated (IP) with anti-MYC antibodies and
immunoblotted with anti-MYD88 antibodies. f, Lysates from HMVEC-d
immunoprecipitated with anti-MYD88 antibodies and immunoblotted with








































































































































Figure 4 | Inhibition of ARF-GEFs decreases collagen-induced vascular
permeability and arthritis inmice. a, Arthritis-induced vascular permeability
in the joint measured by Evans Blue leak 7 days after treatment initiation in the
presence of SecinH3 or Enbrel. n5 14 per group. b, Chronological arthritic
assessment. n5 10 per group. Significance values are measured against CIA
plus vehicle. c, Haematoxylin and eosin staining of sections through joints. Bn,
bone; HC; hyaline cartilage; JS, joint space; Pn, inflamed pannus. Asterisk
denotes cartilage and bone loss; arrows denote eroded cartilage. d, Summary of
histological changes of inflammation, pannus, cartilage and bone damage of
indicated treatment. Control, n5 5; Enbrel and SecinH3, n5 10. Error
bars denote s.e.m. *P, 0.05, **P, 0.01, ***P, 0.001, ****P, 0.0001 versus
disease group.
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Chronic inflammation causes tissue destruction through dysregu-
lated cytokine release, inflammatory cell recruitment and vascular
permeability; yet each of these mechanisms has critical roles in many
physiologic processes, including the immune response5,7. We have
identified a novel pathway that uncouples cytokine effects on vascular
stability from other critical functions of the canonical NF-kB tran-
scription program (Supplementary Fig. 1). Our model suggests the
potential for inhibition of vascular leak without modulation of
immune-cell adhesion or other critical NF-kB-dependent responses.
The activation of many inflammatory cytokine receptors disrupts
cell–cell interactions, precipitating tissue oedema and destruc-
tion5,7,9,27. Toll-like receptors and the interleukin receptor also use
MYD88, and the mechanism described here may well apply3,10.
Interestingly, TNFR1 (also known as TNFRSF1A) does not use
MYD88 yet still activates ARF6–GTP after stimulation (Supplemen-
tary Fig. 9). Whether ARNO or another ARF-GEF binds directly to
TNFR1 or its adaptor protein TRADD is unknown, as is the possibility
that ARF-GEF–ARF6–cadherin serves as a common signalling mo-
dule exploited by multiple cytokines. Although this study focused on
the endothelium, the concept of cytokine receptor–ARF–cadherin
may also apply to the epithelial barrier, which expresses these consti-
tuents and is also compromised by cytokines including IL-1b16.
Inhibition of this novel vascular-stability pathway, which is aimed at
enhancing the resilience of the host to the cytokine response, shows
effects commensurate to those of class-leading drugs that target cyto-
kines upstream of NF-kB and seek to blunt the cytokine response of
the immune system outright. This approachmay be particularly useful
in arthritis, as the current medical therapy can render a patient immu-
nocompromised and susceptible to reactivation of infectious disease
such as tuberculosis28. Application of these findings to other diseases
characterized by excessive acute or chronic inflammatory states,
including sepsis, Crohn’s disease, ulcerative colitis, scleroderma and
psoriasis, should also be considered9,29,30.
METHODS SUMMARY
Transwell permeability.HMVEC-d cells were seeded on 1.0-mmCostar transwell
inserts coated with fibronectin. Cells were grown to confluency and treated with
SecinH3 for 3 h or MAPK/NF-kB/transcription/translation inhibitors for 30min
followed by treatment with 10 ngml21 IL-1b. Alternatively, cells were infectedwith
Ad-GFP or Ad-ARF6(Q67L) for 48h. siRNA knockdown was performed as
described in Supplementary Methods, and cells were treated with IL-1b 72 h after
the second siRNA transfection. Twohours later,HRPwas added to the top chamber
at a final concentration of 100mgml21.Mediumwas removedafter 60min fromthe
lower chamber. For time-course transwell assays and transcription/translation-
inhibitor experiments (Fig. 1a, c, d), HRP was added to the insert at the same time
as IL-1b. Transwell inserts weremoved to fresh wells after each time point, and the
concentration of HRP in the bottom chamber was measured for monolayer per-
meability.HRPwas assessedusingmedia samples obtained from the lower chamber
incubatedwith 0.5mMof guaiacol and 0.6mMH2O2. Spectrophotometric analysis
of absorbance at 490 nm provided a quantitative evaluation of the amount of HRP
that crossed the membrane. Data are presented as mean6 s.e.m. of at least three
independent experiments performed in quadruplicate.
A detailed description of all methods is provided in Supplementary Information.
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Supplementary Figure 1.  3rRpRVeG ,/1ȕ Vignaling patKZayV.  
,/ȕ DFWLYDWHV 1)ț% WKURXJK D 0<',5$.,ț%GHSHQGHQW SDWKZD\  0<' DOVR ELQGV WR $512 DQG WKURXJK 
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Supplementary Figure 2.   ,/ȕinGuFeG permeaEility iV inGepenGent RI 1Fț% (5.2 -1. anG p.  
(a)  +09(&' FHOOV ZHUH VWLPXODWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RI '062 RU 6& DQG VXEMHFWHG WR LPPXQR-
ÀXRUHVFHQFH IRU 1)-ț% JUHHQ :KLWH DUURZV LQGLFDWH QXFOHDU 1)-ț%  (E) +09(&-' FHOOV ZHUH VWLPXODWHG ZLWK 
,/-ȕ LQ WKH SUHVHQFH RI '062 RU WKH 1)-ț% LQKLELWRU 6&- 7UDQVHQGRWKHOLDO UHVLVWDQFH ZDV PHDVXUHG E\ (OHF-
WULF &HOO-VXEVWUDWH ,PSHGDQFH 6HQVLQJ (&,6   (F) 4XDQWL¿FDWLRQ RI  ,/-ȕ-LQGXFHG GLVUXSWLRQ RI SODVPD PHPEUDQH 
9(-FDGKHULQ WUHDWHG ZLWK '062 DQG 6&- DV VKRZQ LQ )LJXUH F  (d) /\VDWHV IURP +09(&-' FHOOV VWLPXODWHG 
ZLWK ,/-ȕ LQ WKH SUHVHQFH RI '062 8 6% RU -1. ,QKLELWRU ,, ZHUH VXEMHFWHG WR LPPXQREORWWLQJ IRU 
S-(5. S-3 RU S--1.  (e) 7UDQVZHOO SHUPHDELOLW\ RI +09(&-' FHOOV VWLPXODWHG ZLWK ,/-ȕ LQ WKH SUHVHQFH 
RI LQKLELWRUV RI (5. 8 3 6% DQG -1. -1. ,QKLELWRU ,,  (I) 7UDQVHQGRWKHOLDO UHVLVWDQFH ZDV 
PHDVXUHG E\ (&,6 LQ +09(&-' FHOOV WUHDWHG ZLWK ,/-ȕ LQ WKH SUHVHQFH RI '062 (5. LQKLELWRU 8 3 
LQKLELWRU 6% RU -1. ,QKLELWRU ,, LQ (*0-09 FRPSOHWH PHGLD (g) 9(-FDGKHULQ LPPXQRÀXRUHVFHQFH RI 
+09(&-' FHOOV WUHDWHG ZLWK ,/-ȕ LQ WKH SUHVHQFH RI '062 8 6% RU -1. ,QKLELWRU ,, :KLWH DUURZV 
LQGLFDWH DUHDV RI UHGXFHG 9(-FDGKHULQ VXUIDFH ORFDOL]DWLRQ (K) 4XDQWL¿FDWLRQ RI J  )RU DOO H[SHULPHQWV 1   DQG 
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6XSSOHPHQWDU\)LJXUH  ,/ȕLQGXFHGSHUPHDELOLW\LVLQGHSHQGHQWRI1)ț%WUDQVFULSWLRQDQGLWVWDUJHWV
(a) +09(&' FHOOV WUHDWHG ZLWK ,/ȕ IRU     RU  KRXUV ZHUH VXEMHFWHG WR TXDQWLWDWLYH 573&5 WR 
DVVHVV 1)ț% WDUJHW JHQH P51$ OHYHOV (E) 7UDQVHQGRWKHOLDO UHVLVWDQFH ZDV PHDVXUHG E\ (&,6 LQ +09(&' 
FHOOV WUHDWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RU DEVHQFH RI D &R[ LQKLELWRU ,QGRPHWKDFLQ (F) &RQGLWLRQDO PHGLD IURP 
+09(&' FHOOV WUHDWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RU DEVHQFH RI ,QGRPHWKDFLQ ZHUH VXEMHFWHG WR (/,6$ IRU 3*( 
(d) 7UDQVHQGRWKHOLDO UHVLVWDQFH ZDV PHDVXUHG E\ (&,6 LQ +09(&' FHOOV WUHDWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RI 
3*( (e) 7UDQVHQGRWKHOLDO UHVLVWDQFH ZDV PHDVXUHG E\ (&,6 LQ +09(&' FHOOV WUHDWHG ZLWK ,/ȕ RU 9(*) LQ 
WKH SUHVHQFH RI DQWL9(*) DQWLERG\ $9$67,1 RU DQ ,J* )& FRQWURO (I) 1)ț% WUDQVFULSWLRQDO WDUJHWV ,&$0 
,/ DQG 71)Į P51$ OHYHOV ZHUH FKHFNHG E\ TXDQWLWDWLYH 573&5 LQ +09(&' FHOOV WUHDWHG ZLWK ,/ȕ LQ WKH 
SUHVHQFH RU DEVHQFH RI $FWLQRP\FLQ' (g) 1)ț% WUDQVFULSWLRQDO WDUJHWV ,/ 0&3 DQG *52D SURWHLQ OHYHOV 
ZHUH FKHFNHG LQ WKH FRQGLWLRQHG PHGLD IURP +09(&' FHOOV WUHDWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RU DEVHQFH RI 
$FWLQRP\FLQ' DQG &\FORKH[LPLGH E\ (/,6$
a b 
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 *** vs Basal
Supplementary Figure 4.  $5F FRnVtitutiYe aFtiYatiRn enKanFeV YaVFular permeaEility
(a) ,PPXQRÀXRUHVFHQFH RI LQWHUQDOL]HG 9(FDGKHULQ JUHHQ LQ ,/ȕ DQG 9(*) VWLPXODWHG +09(&' FHOOV DIWHU 
  DQG  PLQXWHV (E) 4XDQWL¿FDWLRQ RI 9(FDGKHULQ LQWHUQDOL]DWLRQ LQ ,/ȕ DQG 9(*) VWLPXODWHG +09(&' 
FHOOV DIWHU   DQG  PLQXWHV  ,QGXFWLRQ RI 9(FDGKHULQ LQWHUQDOL]DWLRQ E\ ,/ ȕ LV PRUH UDSLG WKDQ WKDW LQGXFHG 
E\ 9(*)  (F) 9(FDGKHULQ DQG (VHOHFWLQ P51$ OHYHOV LQ ,/ȕVWLPXODWHG +09(&' FHOOV (d) /\VDWHV IURP ,/
ȕVWLPXODWHG +09(&' ZHUH LPPXQREORWWHG ZLWK DQWLERGLHV DJDLQVW 9(&DGKHULQ DQG ,&$0 DW YDULRXV WLPH 
SRLQWV (e) +09(&' FHOOV LQIHFWHG ZLWK $G1XOO RU $G$5) 4/ DGHQRYLUXV ZHUH DVVHVVHG IRU WUDQVHQGRWKHOLDO 
UHVLVWDQFH E\ (&,6  (I) 4XDQWL¿FDWLRQ RI )LJXUH H (g) ,PPXQREORWWLQJ IRU 9(FDGKHULQ RI FHOO O\VDWHV RU IURP 
$5) 4/ DGHQRYLUDOYHFWRU LQIHFWHG +09(&' (K) /\VDWHV IURP +09(&' FHOOV WUDQVIHFWHG ZLWK ARF6 RU 
FRQWURO VL51$ ZHUH LPPXQREORWWHG IRU $5) (i) 4XDQWL¿FDWLRQ RI )LJXUH M  )RU DOO H[SHULPHQWV 1   DQG HUURU 
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Supplementary Figure 5.  ,nKiEitiRn RI $5F*$3S Rr $5F*(FV ZitK Vmall mRleFuleV GeFreaVeV Rr inFreaVeV 
9(FaGKerin FellVurIaFe lRFali]atiRn reVpeFtiYely.  
(a) 4XDQWL¿FDWLRQ RI SODVPD PHPEUDQH 9(FDGKHULQ DV VKRZQ LQ )LJXUH F (E) 7UDQVHQGRWKHOLDO UHVLVWDQFH ZDV 
PHDVXUHG E\ (&,6 LQ +09(&' FHOOV WUHDWHG ZLWK '062 RU 46  (F) +09(&' +XPDQ UHWLQDO HQGRWKHOLDO 
FHOOV +5(& DQG +XPDQ XPELOLFDO YHLQ HQGRWKHOLDO FHOOV +89(& ZHUH DQDO\]HG E\ TXDQWLWDWLYH 573&5 IRU 
$5)*() &<7+ ,46(& DQG ()$ IDPLO\ JHQH H[SUHVVLRQ  (d) +09(&' FHOOV VWLPXODWHG ZLWK '062 RU 
6HFLQ+ ZHUH VXEMHFWHG WR LPPXQRÀXRUHVFHQFH IRU 9(FDGKHULQ JUHHQ (e) 4XDQWL¿FDWLRQ RI G  (I) 9(FDGKHULQ 
PHPEUDQH IUDFWLRQ DIWHU WUHDWPHQW ZLWK 6HFLQ+ RU '062 FRQWURO (g) 7UDQVHQGRWKHOLDO UHVLVWDQFH ZDV PHDVXUHG LQ 
+09(&' FHOOV VWLPXODWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RI '062 RU 6HFLQ+ E\ (&,6  (K) 4XDQWL¿FDWLRQ RI )LJXUH 
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Ad-ARNO (WT)  
IL-1` - + - + - +
Control siRNA + + - - - -
ARNO siRNA      - - + + + +
- - - - + +
Ad-Null             + + + + - -
























































(a) /\VDWHV IURP +09(&' FHOOV WUDQVIHFWHG ZLWK Cytohesin-1, ARNO, Cytohesin-3, GEP-100 RU FRQWURO VL51$ 
ZHUH LPPXQREORWWHG IRU &\WRKHVLQ $512 &\WRKHVLQ RU *(3  (E) 7UDQVZHOO SHUPHDELOLW\ RI Cytohesin-1, 
Cytohesin-3, GEP-100 RU FRQWURO VL51$ WUHDWHG +09(&' VWLPXODWHG ZLWK ,/ȕ IRU  KRXUV  :H VKRZ WKDW ORVV 
RI F\WRKHVLQ RU F\RWKHVLQ KDYH QR HIIHFW LQ ,/ȕ LQGXFHG SHUPHDELOLW\ $GGLWLRQDOO\ ZKLOH ORVV RI *(3 
GHFUHDVHV EDVHOLQH SHUPHDELOLW\ WKHUH LV QR HIIHFW RQ WKH IROG LQFUHDVH LQ ,/ȕ LQGXFHG SHUPHDELOLW\ VXJJHVWLQJ 
WKDW *(3 LV UHJXODWLQJ SHUPHDELOLW\ LQGHSHQGHQW RI DQ ,/ȕ SDWKZD\ (F) 4XDQWL¿FDWLRQ RI )LJXUH N  (d) 
+09(&' WUHDWHG ZLWK ARNO RU FRQWURO VL51$ ZHUH VWLPXODWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RU DEVHQFH RI $G 
$5120<& RU $G1XOO WKHQ DVVD\HG E\ *73$5) SXOOGRZQ DQG LPPXQREORWWHG ZLWK $5) DQWLERGLHV (e) 
+09(&' WUHDWHG ZLWK ARNO RU FRQWURO VL51$ ZHUH LQIHFWHG ZLWK $G1XOO RU ARNO VL51$ UHVLVWDQW $G$512
0<& WKHQ VWLPXODWHG ZLWK ,/ȕ DQG  DVVD\HG E\ WUDQVZHOO SHUPHDELOLW\ DVVD\  (I) 4XDQWL¿FDWLRQ RI FHOOVXUIDFH 
9(FDGKHULQ LQ +09(&' WUHDWHG ZLWK ARNO RU FRQWURO VL51$ DQG LQIHFWHG ZLWK $G1XOO RU ARNO VL51$ 
UHVLVWDQW $G$5120<& WKHQ VWLPXODWHG ZLWK ,/ȕ DV LQ H  (g) ,PPXQREORW IRU ELRWLQODEHOHG LQWHUQDOL]HG 9(
FDGKHULQ DIWHU ,/ȕ VWLPXODWLRQ LQ FRQGLWLRQV GHVFULEHG LQ H DQG I  )RU DOO H[SHULPHQWV 1   DQG HUURU EDUV 
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6XSSOHPHQWDU\ )LJXUH   7KH ,/ȕLQGXFHG SHUPHDELOLW\ SDWKZD\ GLYHUJHV IURP WKH FDQRQLFDO1)ț%
SDWKZD\DW0<' 
(a) /\VDWHV IURP +09(&' FHOOV WUDQVIHFWHG ZLWK IRAK1 RU FRQWURO VL51$ ZHUH LPPXQREORWWHG IRU ,5$. 
(E) /\VDWHV IURP +09(&' FHOOV WUDQVIHFWHG ZLWK MYD88 RU  FRQWURO VL51$ ZHUH LPPXQREORWWHG IRU 0<' 
(F) )OXRUHVFHQFHDFWLYDWHG FHOO VRUWLQJ IRU (VHOHFWLQ ,&$0 DQG 9&$0 FHOO VXUIDFH ORFDOL]DWLRQ RI 
+09(&' VWLPXODWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RI '062 RU 6HFLQ+ (d) 4XDQWLWDWLYH 573&5 IRU E-selectin, 
ICAM-1 DQG VCAM-1 RI +09(&' VWLPXODWHG ZLWK ,/ȕ LQ WKH SUHVHQFH RI '062 RU 6HFLQ+ (e) 4XDQWL¿FDWLRQ 
RI KXPDQ SRO\PRUSKRQXFOHDU OHXNRF\WH UROOLQJ DQG DGKHUHQFH WR D +09(&' PRQROD\HU XQGHU VKHDU VWUHVV 
FRQGLWLRQV (I) (g) /\VDWHV IURP +(. 7 FHOOV H[SUHVVLQJ 0<'+$ DQG WKH LQGLFDWHG $5)*()0<& 
FRQVWUXFWV ZHUH LPPXQRSUHFLSLWDWHG ZLWK DQWL+$ DQWLERGLHV DQG LPPXQREORWWHG ZLWK DQWL0<& DQWLERGLHV )RU 

































































































































































































(a) 7LPHOLQH RI WKH FROODJHQLQGXFHG DUWKULWLV DVVD\  $UWKULWLV ZDV LQGXFHG E\ WZR FROODJHQ LQMHFWLRQV  GD\V DSDUW 
0LFH ZHUH VHJUHJDWHG LQWR SRROV DQG WUHDWPHQW ZLWK 6HFLQ+ (QEUHO RU 9HKLFOH &RQWURO ZDV LQLWLDWHG DIWHU WKH 
RQVHW RI GLVHDVH (YDQV %OXH H[SHULPHQWV ZHUH SHUIRUPHG VHYHQ GD\V DIWHU WUHDWPHQW LQLWLDWLRQ  &OLQLFDO VFRUHV ZHUH 
UHFRUGHG GDLO\ IURP WKH GD\ RI WUHDWPHQW LQLWLDWLRQ XQWLO WKH H[SHULPHQW HQGHG  GD\V ODWHU  (E) 0HDVXUHPHQW RI 
F\WRNLQH OHYHOV ZLWKLQ DUWKULWLF MRLQWV  KRXUV SRVW WUHDWPHQW LQLWLDWLRQ  ,Q DQ DLUSRXFK PRGHO RI DFXWH LQÀDPPDWLRQ 
H[XGDWH YROXPH (F) DV ZHOO DV WKH ZKLWH EORRG FHOO FRQFHQWUDWLRQ (d) LQ WKH H[XGDWHV ZDV PHDVXUHG LQ WKH YHKLFOH 
6HFLQ+ RU (QEUHOWUHDWHG PRXVH VL[ KRXUV DIWHU LQÀDPPDWRU\ VWLPXOXV (UURU EDUV UHSUHVHQW 6(0 IRU  PLFH SHU 
JURXS    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Supplementary Figure 9. 71FĮ aFtiYateV $5F in enGRtKelial FellV.  
+09(&' FHOOV VWLPXODWHG ZLWK 71)Į ZHUH DVVD\HG E\ $5)*73 SXOO GRZQ DVVD\ DQG WKHQ LPPXQREORWWHG ZLWK 
































Human dermal microvascular endothelial cells (HMVEC-D) were purchased at passage 0 from 
Lonza and used at passages 2-6.  SecinH3, ERK1/2 signal pathway inhibitor (U0126), P38 signal 
pathway inhibitor (SB203580), JNK signal pathway inhibitor (JNK Inhibitor II), and NF-B 
signal pathway inhibitor (SC-514) were from Calbiochem.  QS11 was from Sigma. Rabbit anti-
VE-cadherin antibody, rabbit anti-MYD88 antibody (#3699 for western blot, #4283 for 
immunoprecipitation), rabbit anti-IRAK1 antibody, rabbit anti-p-ERK1/2, rabbit anti-p-P38, 
rabbit anti-p-JNK antibody, rabbit anti-ERK1/2, rabbit anti-P38 antibody, rabbit anti-JNK 
antibody and rabbit anti-NF-B P65 antibody were from Cell Signaling.  Mouse anti-ARF6 
antibody was from Millipore.  Mouse anti-ARNO antibody was from Abnova.  ARF6 siRNA, 
ARNO siRNA, MYD88 siRNA and IRAK1 siRNA were from Qiagen.    
 
Transfection and siRNAs 
 
siRNAs were diluted in 12.5% HiPerFect Transfection Reagent (Qiagen) in Optimem 
(Invitrogen) and incubated 10-20 minutes at room temperature. As siRNAs were sitting, passage 
3-4 HMVEC-D cells were passaged and resuspended in EGM2-MV (Endothelial Cell Basal 
medium-2 supplied with EGM®-2 MV SingleQuots®, Lonza) and combined with siRNAs such 
that the final concentration of siRNA was 30nM (all targets). The cells were plated, allowed to 
grow overnight and then the growth media was replaced. Three days after the initial transfection, 
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The following is a table of all siRNAs used, their catalogue numbers, sequence, the location 
within the gene the siRNA targets, and average knockdown observed by western blot. 
Gene Catalogue 
Number 
Target sequence (5’-3’) Region Mean 
knockdown 
ARF6 SI02757286 CAACGTGGAGACGGTGACTTA exon 77% 
ARNO SI00061299 CACGCTGTTGGTAATCTTATT 3’ UTR 63% 
Cytohesin-1  SI04217185 CGGGACAGAGGTTCCGGATAA 3’ UTR 93% 
Cytohesin-3 SI00061257 CAGCATGTTGTGCTCGGACAA 3’ UTR 99% 
MYD88 SI00300909 AACTGGAACAGACAAACTATC exon 87% 
IRAK1 SI00605262 CCGGGCAATTCAGTTTCTACA exon 83% 
 
Protein expression constructs 
The coding sequence of full-length MYD88 (BC023589), ARNO (BC038713), CYTH-1 
(BC038385), CYTH-3 (BC028717) and GEP100 (BC010267) were amplified by PCR from 
IMAGE cDNA clones and ligated into a pcDNA3.1 vector after enzyme digestion.  The ARNO, 
CYTH-1, CYTH-3 and GEP100 constructs contained both MYC and HIS epitopes, while the 
MYD88 construct contained an HA epitope.   
Subcellular fractionation 
Subcellular fractionation was performed as previously described9.  Briefly, HMVEC-D cells 
were infected with adenovirus for 48 hours, stimulated with QS11 for 3 hours, or stimulated with 
SecinH3 for 2 hours.   Alternatively, cells were transfected with siRNA as described above.  The 
monolayer was washed two times with ice-cold phosphate-buffered saline (PBS) containing Ca2+ 





1 2  |  W W W. N A T U R E . C O M / N A T U R E
RESEARCH
protease inhibitors (Roche) and phosphatase inhibitors (Sigma), and dithiothreitol 1mM].  After 
the third wash, cells were homogenized in a Dounce homogenizer using 20 strokes.  The 




The resuspended pellet was centrifu?=<9L
?>GJEAFML=K9LX
9F<L@=KMH=JF9L9FL
was saved as a soluble membrane fraction.  To obtain the total cell lysate, an aliquot of cellular 
material was set aside before Dounce homogenization.  RIPA buffer was added to this aliquot 
and theFL@=EAPLMJ=O9K;=FLJA>M?=<9L
?>GJEAFML=K9LX/@=J=KMDLAF?
supernatant was saved for use as total cell lysate.  Densitometry was performed on at least three 
independent experiments and data are presented as mean ± SEM. 
ARNO Rescue Experiment 
=DDK106 in a 10 cm dish) were first transfected with ARNO siRNA (SI00061299, Qiagen) 
at 30nM and changed to fresh media 24 hours after the transfection. The siRNA was directed 
against sequences in the 3’ UTR of the endogenous ARNO mRNA.  48 hours after the media 
change, cells were harvested and underwent a second transfection with the same siRNA at the 
K9E=<GK==DDKO=J=L@=FAF>=;L=<OAth either an Ad-ARNO (WT) or Ad-ARNO (E156K) virus 
(5107 p.f.u.ml-1) 36 hours after the second siRNA transfection and incubated for 36 hours2.  The 
adenoviral vectors expressing human ARNO (or mutant ARNO) fused to a (4-epitope tag did 
not contain a 3’UTR ARNO sequence, and was thus predicted to be resistant to the siRNA.  
ARF6-GTP pull down assay:  ARF6-GTP pull-down assays were performed as described21.  
JA=>DQ
#(1 -D cells were pre-LJ=9L=<OAL@.=;AF#>GJ@GMJK>GDDGO=<:QLJ=9LE=FLOAL@
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10ng/mL IL-1.  Alternatively, cells were transfected with siRNA as described above.  Cells 
were treated with IL-1 72 hours after the second siRNA transfection for 5 minutes. After 
treatment, media was aspirated and cells were rinsed with chilled Ultrasaline. Dishes were frozen 
on dry ice.  Following thawing, ARF6 pulldown lysis buffer [Tris-HCl 50mM, NaCl 100mM, 
MgCl21mM, NP-40 1%, glycerol 10%, protease inhibitors (Roche) and phosphatase inhibitors 
(Sigma)] were added to cells.  Lysates were centrifuged and supernatants were added to GGA3-
conjugated beads (Cell Biolabs, sta-40706), and agitated at 4°C for 60 minutes.  Beads were 
washed in ARF6 pulldown lysis buffer and resuspended in 2X Laemmli prior to loading on 15% 
SDS-PAGE gels. A fraction of the cell lysate was withheld for use as a measure of total ARF6 in 
each sample. Data are presented as mean ± SEM of at least three independent experiments.    
Quantitative PCR 
Total RNA was extracted from cells using the RNeasy plus mini kit (Qiagen) according to 
manufacturer’s instructions.  RNA was converted to cDNA using RETROscript® kit (Ambion).  
Quantitative RT-PCR was performed using TaqMan probes (CYTH1, Hs00245092; ARNO, 
Hs00244669; CYTH3, Hs00188456; CYTH4, Hs00203581; IQSEC1, Hs00208333; IQSEC2, 
Hs00390333; IQSEC3, Hs01006522; EFA6A, Hs00160539; EFA6B, Hs00260268; EFA6C, 
Hs00209633; EFA6D,Hs00202892; VEGFA, Hs00900055; ICAM1, Hs00164932; VCAM1, 
Hs01003372; IL-6, Hs9999032; TNF, Hs01113624_g1; Cox2, Hs00153133; VE-cadherin, 
Hs00901463; E-selectin, Hs00174057_m1) and the ABI Prism 7900 HT Real-Time PCR System 
(Applied Biosystems).  Quantification was performed using a human brain cDNA standard curve 
and normalized to 18S rRNA. Data are presented as mean ± SEM of four duplicates from at least 
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Immunofluorescence 
10,000 HMVEC-D cells were seeded onto 8 well chamber slides coated with human fibronectin. 
Cells were pre-treated with small molecule inhibitors of NF-B or MAPK for 30 minutes or 
SecinH3 for 3 hours followed by treatment with 10 ng/ml IL-1 for 2 hours.  Alternatively, cells 
were infected with 1105-1108 p.f.u.ml-1 of the indicated adenovirus for 48 hours. For siRNA 
knockdown experiments, cells were harvested 72 hours after the first siRNA transfection, re-
transfected with the same siRNA a second time and seeded onto chamber slides. 72 hours after 
the second siRNA transfection, cells were treated with IL-1 for 2 hours. Cells were fixed, 
permeabilized, blocked with normal donkey serum and stained for VE-cadherin or NF-B p65.  
The only exception to this protocol was for Supplementary Fig. 6f, where permeabilization was 
not performed in order to increase the signal of cell-surface VE-cadherin.  Images are maximum-
Z-projections of confocal images acquired at 0.3 µm z-section intervals.  Image acquisition 
settings were identical for all images.  Images are representative of at least 3 independent 
experiments. Quantification was performed using a custom Image-J macro that imported images, 
applied a threshold to exclude all but intensely-stained areas, and returned this area as an output.  
Identical threshold and size restriction values were used to analyze all images. Data are presented 
as mean ± SEM of at least three independent experiments. 
Immunoprecipitation 
Immunopreciptation assays were performed as described9.  Briefly, HMVEC-D cells were 
treated with 10 ng/ml IL-1 for 1 and 5 minutes. For Figure 3e, HMVEC-D cells were infected 
with 1  107 p.f.u.ml-1 Ad Null or Ad-ARNO-MYC 48 hours before IL-1 treatment. Cells were 
then washed with ice-cold PBS and lysed with ice-cold lysis buffer (Tris-HCl 50 mM, NaCl 
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250mM, NP-40 1%, and glycerol 10% with protease inhibitors and phosphatase inhibitors). Cell 
lysates were centrifuged for 15 minutes at 13,000g and the supernatants saved. A BCA assay 
(Pierce) was used to determine protein concentrations. Lysates were incubated with 8 mg of the 
indicated antibody and protein A/G–Sepharose (Santa Cruz Biotechnology) for 1 hour at 4°C.  
Beads were then washed 5 times in lysis buffer. The immunoprecipitates were assayed by 
western blot analysis using Peroxidase-conjugated AffiniPure Light Chain Specific secondary 
antibody for signal detection. Data represents at least 3 independent experiments. 
Biotinylation Assay 
HMVEC-D cells were transfected with ARNO siRNA or control siRNA and then infected with 
Ad null or Ad-ARNO (as described), and grown to 100% confluence on 100-mm dishes. Cells 
were washed with ice-cold PBS three times and labeled with EZ-link Sulfo-NHS-SS-Biotin 
(Thermo) at 0.5mg/ml in PBS for 30 minutes on ice. Excess Biotin was removed by washing 
with glycine in PBS two times on ice. The cells were then incubated with 10 ng/ml IL-1 and 0.6 
mM Primaquine (MP Biomedicals) at 37°C for 30 minutes; they were then exposed to GSH 
buffer (Glutathione 50mM, NaOH 75mM, NaCl 75mM, EDTA 1mM, BSA 0.1%, PH 9.0) on ice 
for 20 minutes to remove surface biotin. GSH was then quenched by washing with 5 mg/ml 
iodoacetamide in PBS. After an additional wash with ice-cold PBS, cells were lysed in NP-40 
buffer (Tris-HCl 50 mM, NaCl 150 mM, MgCl2 1mM, NP-40 1%, Glycerol 10%) with a 
protease inhibitor cocktail on ice. Cell lysates were centrifuged at 14,000 rpm for 15 minutes and 
supernatant was incubated with High Capacity Streptavitin Agarose Resin (Thermo) for 60 
minutes at 4°C. Beads were washed with NP-40 lysis buffer three times. Bound proteins were 
released in 2Laemmli buffer with 5% -mercaptoethanol at 95°C and internalized VE-cadherin 
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Transendothelial resistance 
Transendothelial resistance was measured by Electric Cell-substrate Impedance Sensing (ECIS).  
An 8W10E+ electrode culture array (Applied Biophysics) was coated with 10 g/mL human 
fibronectin.  5 x 104 HMVEC-D per well were seeded in complete media onto the electrode 
culture array and monitored until a stable monolayer formed.  A stable monolayer was indicated 
by a capacitance <10 nF at 6.4 x 104 Hz and a stable resistance over several hours at 4 x 103 Hz.  
Cells were pre-treated with SecinH3/Avastin for 3 hours or MAPK/NF-B inhibitors or 
Indomethacin or PGE2 for 30 minutes followed by treatment with 10 ng/ml IL-1 (unless 
otherwise indicated).  Alternatively, cells were infected with Ad-GFP or Ad-ARF6 (Q67L) 
adenoviruses.  Resistance across the monolayer using alternating current at a frequency of 4 x 
103 Hz was measured by 40 electrodes per well (1000-2000 cells) using the ECIS-Z system 
(Applied Biophysics) and reported in Ohms or normalized to control treatment or initial 
resistance.  Conditioned media was collected from cells undergoing ECIS (Supplemental Figure 
2e) at 16 hours after treatment with IL-1 in the presence of DMSO or inhibitors.  PGE2 
concentration was calculated using the PGE2 Express EIA kit from Cayman Chemical (500141) 
according to manufacturer’s instructions.  Data are representative of at least 3 independent 
experiments or represented as mean ± SEM. 
Transwell permeability 
HMVEC-D cells were seeded on 1.0 µm Costar transwell inserts coated with fibronectin.  Cells 
were grown to confluency and treated with SecinH3 for 3 hours or MAPK/NF-
B/transcription/translation inhibitors for 30 minutes followed by treatment with 10ng/ml IL-1. 
Alternatively, cells were infected with Ad-GFP or Ad-ARF6 (Q67L) adenovirus for 48 hours. 
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siRNA knockdown was performed as described and cells were treated with IL-1 72 hours after 
the second siRNA transfection.  Two hours later, horseradish peroxidase (HRP) was added to the 
top chamber at a final concentration of 100µg/ml. Medium was removed after 60 minutes from 
the lower chamber.  For time-course transwell assays and transcription/translation inhibitor 
experiments (Figure 1a, d), HRP was added to the insert at the same time as IL-1.  Transwell 
inserts were moved to fresh wells after each timepoint, and the concentration of HRP in the 
bottom chamber was measured for monolayer permeability. HRP was assessed using media 
samples obtained from the lower chamber incubated with 0.5 mM of guaiacol and 0.6 mM H2O2.  
Spectrophotometric analysis of absorbance at 490 nm provided a quantitative evaluation of the 
amount of HRP that crossed the membrane. Data are presented as mean ± SEM of at least three 
independent experiments performed in quadruplicate. 
Fluorescence-Activated Cell Sorting (FACS) 
FACS was performed as decribed31.  HMVEC-D were pre-treated with SecinH3 for 3 hours and 
then stimulated with 10 ng/ml IL-1 for 4 hours.  Analysis of the cell surface localization of 
adhesion molecules was performed with one step immunofluorescence staining using anti-hE-
selectin-FITC, anti-hICAM1-FITC and anti-hVCAM1-PE antibody (BD).  Data are presented as 
mean ± SEM of at least three independent experiments. 
Leukocyte Rolling and Adherence assay 
3 x 104 HMVEC-D were seeded into each well of a fibronectin-coated parallel plate flow 
chamber (U-plate 0.4 VI Fibronectin, Ibidi GMBH).  Media was changed daily using gentle 
aspiration until the cells had grown to confluence (approximately 3-5 days).  Human 
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described protocols32,33.  Briefly, human peripheral venous blood (500 mL) from healthy, 
medication-free, fasting adult subjects was drawn into acid-citrate-dextrose (1.4 mL ACD/8.6 
mL blood) through standard venipuncture technique and used immediately upon collection.  The 
University of Utah Institutional Review Board approved this study and all subjects provided 
informed consent.  Blood was centrifuged at 150 x g for 20 minutes at 20oC to separate platelet-
rich plasma (PRP) from red and white blood cells (RBC/WBC).  The PRP was removed and the 
remaining RBC/WBC mixture was resuspended in 0.9% sterile saline back to the original 
volume.  A volume equaled to half the original blood volume of 6% Dextran 70 (Sigma-Aldrich, 
St. Louis, MO) was then added to the RBC/WBC mixture and left for one hour. The leukocyte-
rich supernatant was removed and centrifuged at 400 x g for five minutes a 4oC.  The supernatant 
was then removed and the pellet resuspended (in 0.2% NaCl followed by an equal part of 1.6% 
NaCl), and the cells were centrifuged at 400 x g for five minutes at 4oC.  After centrifugation, the 
cells were resuspended in Hank’s Balance Salt Solution (Sigma-Aldrich, St. Louis, MO) with 1% 
human serum albumin (HBSS/A) (University of Utah Hospital, Salt Lake City, UT) and layered 
over an equal volume of Ficoll-Paque Plus (GE Healthcare Biosciences, Piscataway, NJ).  The 
layered cells were then centrifuged for 30 minutes at 400 x g at 4oC.  After 30 minutes, the 
mononuclear leukocyte layer was removed, followed by the RBC layer, HBSS/A layer, and 
Ficoll-Paque layer.  The remaining pellet containing greater than 95% PMNs was washed with 
HBSS/A and resuspended to 1 x 106 ml-1 in warmed ultrasaline (Lonza).  Endothelial cells in 
parallel-plate flow chambers were pretreated with IL-1 (10 ng/mL) and/or SecinH3 for 3 hours.  
A syringe pump (Harvard Apparatus) was used to flow the PMN solution through the parallel 
plate flow chambers at 1 dynes x cm-1 (a typical venous shear stress).  Differential Interference 
contrast microscopy (DIC) images were taken once per second using an Olympus inverted 
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microscope, and the total number of PMNs rolling and adhered in a 5 minute period were 
quantified using MetaMorph (Olympus) software.  The data is presented as fold over IL-1 
induced leukocyte rolling ± SEM and represents three independent experiments, each consisting 
of at least 3 replicates for each condition.   
Internalization assay 
VE-cadherin internalization assay was performed as previously described9.  Briefly, HUVEC 
were transfected with siRNA as described above and seeded onto 8-well chambered coverglass 
at 5 x 104;=DDK;GN=J?D9KK>L=J@GMJK
L@=;MDLMJ=O9K;@ADD=<9LX>GJEAFML=K

surface-labeled for 60 minutes on ice with 1 ug/mL dialyzed anti-VE Cadherin antibody (clone 
BV6, Millipore) in ice-cold labeling buffer (3% BSA in MCDB131 medium, Invitrogen).  At the 
end of 60 minutes, the labeling buffer was removed and the cells were treated with 0.6 mM 
Primaquine plus vehicle or 10 ng/mL IL-1, DMSO vehicle or 30 M SecinH3 or 50 M SC-
>GJEAFML=K9LX9F<*(GFGD9Q=JKO=J=O9K@=<LAE=s over 10 minutes 
with ice-cold HBSS (HBSS - Hank's Balanced Salt Solution, Invitrogen) + 50mM Glycine + 3% 
BSA, pH 2.7 to remove surface VE-cadherin.  One well for each condition was washed in a 
neutral pH solution to retain surface VE-cadherin staining.  Subsequently, monolayers were fixed 
immediately in 3% paraformaldehyde for 10 minutes.  The VE-cadherin antibody was detected 
using an Alexa-Fluor 488 conjugated anti-Mouse IgG antibody and traditional 
immunofluorescence methods.  To image the monolayers, five images per well were randomly 
selected using the DAPI channel at 600x.  Z-series images were taken using a confocal Olympus 
FV1000IX81 microscope.  Each treatment was done in triplicate.  The assay score represents the 
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Collagen-induced arthritis 
Collagen-induced arthritis (CIA) studies were conducted by Washington Biotechnology using 
their standard procedures and DBA/1J mice as previously published34-38.  All protocols were 
approved by their IACUC (Institutional Animal Care and Use Committee) prior to initiation of 
the study.  Six to seven week old male DBA/1 mice were used (Jackson Laboratories) with 5-20 
animals per group. Bovine type-II collagen (Chondrex) was dissolved in 0.01 M acetic acid, and 
an emulsion with 50 µl of Complete Freund’s Adjuvant was injected at the base of the tail at Day 
0.  21 days following the first injection, a booster injection consisting of a 50 µL emulsion of 
collagen in Incomplete Freund’s Adjuvant was injected at the base of the tail.  Arthritic index 
(AI) was scored for each limb of an animal as follows:  0 = no visible effects of arthritis, 1 = 
edema and erythema of one digit or joint, 2 = edema and erythema of two joints, 3 = edema and 
erythema of more than 2 joints, 4 = severe arthritis of the entire paw and digits accompanied by 
deformity of the limb.  The score for each limb was summed, with 16 as the highest possible AI 
score for each animal.  Treatments were either vehicle (0.5% DMSO/saline IP BID), SecinH3 
(0.1 mg/kg IP BID), or the positive control, Enbrel® (10 mg/kg SC OD).  The experiment was 
repeated multiple times with different endpoints; detailed descriptions of the exact timing for 
each experiment follow.  In all cases, treatment was initiated after mild arthritis was established 
(therapeutic treatment).  
EVAN’s BLUE DYE EXTRAVASATION:  Treatment was initiated when the average arthritic 
index for each group was between 3.4 - 3.55 and all mice in each group demonstrated a positive 
arthritic index.  Due to the variation in when each group reached an average arthritic index of 3.4 
– 3.55, treatment initiation day varied from study day 28 (seven days after the second collagen 
injection) to study day 30 (nine days after the second collagen injection).  The treatments lasted 
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for seven days until the mice were sacrificed for the Evan’s Blue Dye Assay (described in detail 
in subsequent methods). 
ARTHRITIS PROGRESSION:  Treatment was initiated when the average arthritic index for 
each group was 3.1 and all mice in each group demonstrated a positive arthritic index. Due to the 
variation in when each group reached an average arthritic index of 3.1, treatment initiation day 
varied from study day 28 (seven days after the second collagen injection) to study day 29 (eight 
days after the second collagen injection).  The treatments lasted for 13 days in all groups with 
arthritic index recorded regularly throughout. 
HISTOPATHOLOGIC PATTERNS:  Treatment was initiated when the average arthritic index 
for each group was between 3.1-3.2 and all mice in each group demonstrated a positive arthritic 
index.  Due to the variation in when each group reached an average arthritic index of 3.1 - 3.2, 
treatment initiation day varied from study day 29 (eight days after the second collagen injection) 
to study day 33 (12 days after the second collagen injection).  The treatments lasted for 14 days 
in all groups before joints were harvested for histology.  Limbs were preserved in 10% neutral 
buffered formalin for histology.  Limbs were decalcified in formic acid for 2-3 days, paraffin 
embedded, and 8 µm sections stained with toluidine blue.  Arthritis severity was evaluated for 
inflammation, pannus, cartilage damage, and bone damage.  
CYTOKINE EVALUATION:  Treatment was initiated when the average arthritic index for each 
group was 3.4 and all mice in each group demonstrated a positive arthritic index.  All groups 
reached an average arthritic index of 3.4 on day 34 (13 days after the second collagen injection), 
and treatment was initiated.  The treatments lasted for 1 day, at which time plasma and ankle 
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All selection and later scoring were blinded to treatment.  Data are represented as mean ± SEM. 
CIA - Cytokine or chemokine array 
CIA was induced as described.  24 hours after treatment of SecinH3, joints of mice were 
collected and pulverized using a mortar and pestle filled with liquid nitrogen. Tissue was 
transferred to 15 ml tubes, resuspended in 1 ml PBS and homogenized using a Polytron tissue 
homogenizer (PRO Scientific Inc. USA) for 20 s. Mouse joint homogenates were centrifuged for 
10 minutes at 500 g at 4°C. Supernatants were transferred to 1.5 ml Eppendorf tubes, centrifuged 
at 15,000 g for 5 minutes and collected for cytokine analysis by Quansys Biosciences. Data are 
presented as mean ± SEM for 6 mice per condition.  
CIA – Evans Blue permeability 
CIA was induced as described.  Seven days after randomization and treatment initiation, mice 
were given an IV injection of 5 ml/kg of 1% Evans Blue dye.  One hour later, mice were bled 
and plasma collected.  Mice were perfused, the hind limbs degloved, and ankle joints 
homogenized in 0.5 ml saline.  1.5 ml formamide was added and Evans Blue dye eluted 
overnight at 60°C.  Supernatant and plasma samples were read spectrophotometrically and 
expressed as OD620-OD740 joints divided by OD620-OD740 plasma.  Values were normalized 
to non-CIA-induced mice and expressed as fold increase over control.  N=14 per group and data 
are represented as mean ± SEM. 
Air-Pouch Model 
The Carrageenan-induced Air Pouch Model was performed by Washington Biotechnology as 
previously described39-41.    All protocols were approved by their IACUC (Institutional Animal 
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Care and Use Committee) prior to initiation of the study.  Six to seven week old male Swiss-
Webster mice were used (Harlan) with 6-8 animals per group.  On day 0, the nape of the neck 
was shaved and six mL of sterile air was injected subcutaneously.  On day 3, three mL of sterile 
air was injected subcutaneously.  On days 4 and 5, mice that were to be induced at a later time 
were injected with either 0.1 mg/kg SecinH3 IP BID, vehicle IP BID, or 10 mg/kg Enbrel® SQ 
QD.  On day 6 an additional injection was administered one hour prior to carrageenan 
injection.  One mL of 3% carrageenan (FLUKA) previously prepared in de-ionized water with 
heat, or 1mL of saline for the sham group, was then injected into the air pouch.  Four hours after 
carrageenan injection, the mice were anesthetized and 3mL of 10 U/mL heparinized saline was 
injected into the air pouch.  The air pouch was gently massaged, the contents immediately 
removed, and the exudate volumes recorded.  An aliquot of the exudate was transferred to 
heparin-treated microtainer tubes for differential white blood cell counting.  Samples with 
bloody exudates were discarded from white blood cell counting. 
Statistical analysis  
For the majority of data, one-way ANOVA (analysis of variance) with Tukey’s post-hoc test was 
used to assess statistical significance.  A Student’s t-test was used when the experiment was only 
composed of two groups. Two-way ANOVA with Bonferroni post-hoc test was used to assess 
statistical significance for data shown in Figure 4b. A P-value of less than 0.05 was considered 
statistically significant.  Unless otherwise noted, P-values of less than 0.05 are denoted with a 
single symbol (ie. *); P-values less than 0.01 are denoted with two symbols (ie **); P-values less 
than 0.001 are denoted with three symbols (ie ***); P-values less than 0.0001 are denoted with 
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CHAPTER 3 
 
ARF6 INHIBITION STABILIZES THE VASCULATURE AND ENHANCES 
SURVIVAL DURING ENDOTOXIC SHOCK 
 
The following chapter was reprinted with permission from the American Association of 
Immunology. My co-authors were Weiquan Zhu, Christopher C. Gibson, Jay Bowman-
Kirigin, Lise Sorensen, Jing Ling, Huiming Sun, Sutip Navankasattusas, and Dean Y. Li.  
In this manuscript published in the Journal of Immunology, May 16, 2014, 
doi:10.4049/jimmunol.1400309,  we showed that a MYD88-ARNO-ARF6 axis controls 
permeability induced by bacterial lipopolysaccharides and we characterized an inhibitor 
of ARF6 that reduces vascular permeability in both in vitro and in vivo settings as well as 
enhances survival in lethal endotoxemia models. Also in this chapter is an appendix 
including a set of experiments that describes the antimicrobial nature of an inhibitor of 
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ARF6 Inhibition Stabilizes the Vasculature and Enhances
Survival during Endotoxic Shock
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The vascular endothelium responds to infection by destabilizing endothelial cell–cell junctions to allow fluid and cells to pass into
peripheral tissues, facilitating clearance of infection and tissue repair. During sepsis, endotoxin and other proinflammatory
molecules induce excessive vascular leak, which can cause organ dysfunction, shock, and death. Current therapies for sepsis
are limited to antibiotics and supportive care, which are often insufficient to reduce morbidity and prevent mortality. Previous
attempts at blocking inflammatory cytokine responses in humans proved ineffective at reducing the pathologies associated with
sepsis, highlighting the need for a new therapeutic strategy. The small GTPase ARF6 is activated by a MyD88–ARNO interaction
to induce vascular leak through disruption of endothelial adherens junctions. In this study, we show that the MyD88–ARNO–
ARF6–signaling axis is responsible for LPS-induced endothelial permeability and is a destabilizing convergence point used by
multiple inflammatory cues. We also show that blocking ARF6 with a peptide construct of its N terminus is sufficient to reduce
vascular leak and enhance survival during endotoxic shock, without inhibiting the host cytokine response. Our data highlight the
therapeutic potential of blocking ARF6 and reducing vascular leak for the treatment of inflammatory conditions, such as
endotoxemia. The Journal of Immunology, 2014, 192: 000–000.
T he innate immune system is the first line of defense againstpathogenic microbes. It facilitates the recognition of mi-crobial components, such as endotoxin, and initiates an in-
flammatory response that clears the invading organism and promotes
reconstruction of damaged tissues. People with sepsis often have
a frenetic inflammatory response and associated excess vascular
leak that leads to tissue edema, organ failure, shock, and often death
(1–3). Current treatment options are limited to supportive care and
antibiotic therapies (4). Unfortunately, even with these options
mortality still occurs in .25% of septic patients and occurs with
even greater incidence in patients whose condition progresses to
septic shock (5, 6).
The vast majority of therapeutic interventions for sepsis, outside of
antibiotic therapies and supportive care, have focused on reducing the
inflammatory and cytokine responses (7). These approaches, which
include immunosuppression by steroids (8), inhibition of the in-
flammatory TLR4 with eritoran (9), and, in particular, direct inhi-
bition of cytokines, such as TNF-a (10–12), have been successful in
some animal models, but they have produced conflicting or negative
outcomes in human phase III clinical trials. Because of this, alter-
native inflammatory pathways important to the pathology of sepsis
need to be identified to exploit their potential as therapeutic targets.
The recognition of microbial components by TLRs is critical to the
inflammatory response during sepsis. TLRs are expressed in many
cell types and stimulate a MyD88-mediated cascade, which leads to
activation of the inflammatory transcription factor NF-kB and to the
subsequent cytokine storm observed during sepsis (13, 14). We re-
cently identified an association between MyD88 and the guanine
nucleotide exchange factor ARNO. IL-1b requires this association to
activate ARF6 and to induce vascular leak in a process independent
of MyD88’s canonical role in NF-kB–mediated inflammatory gene
expression (15). This MyD88–ARNO–ARF6 cascade promotes en-
hanced vascular permeability through the internalization of vascular
endothelial-cadherin (VE-cadherin). MyD88 is a critical adapter
protein used by numerous other inflammatory pathways, including
IL-18R and most of the described TLRs (14). Therefore, we hy-
pothesized that TLR stimulation may induce vascular permeability
independent from cytokine expression, that this permeability is
mediated by a MyD88–ARNO–ARF6 cascade, and that blocking
ARF6 would enhance survival in models of sepsis.
Materials and Methods
Reagents
Human dermal microvascular endothelial cells (HMVEC-Ds) were pur-
chased at passage 0 from Lonza; experiments were performed at passages
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3–6. The IKKb/NF-kB inhibitor, SC-514, was purchased from Calbio-
chem. The IKK-ε/IRF3 inhibitor, BX-795, was purchased from EMD
Millipore. Small interfering RNAs (siRNAs) were purchased from QIA-
GEN. Salmonella enterica serotype enteritidis LPSs were purchased from
Sigma: catalog number L7770 was used for in vitro experiments, and
catalog number L6011 was used for in vivo experiments. Endothelial cells
were cultured in EGM-2MV (Lonza).
siRNAs
siRNAs were diluted in 12.5% by volume HiPerFect Transfection Reagent
(QIAGEN) in Opti-MEM (Invitrogen) and incubated for $10 min at room
temperature. Passage 3–4 endothelial cells were trypsinized, resuspended
in growth media, and combined with siRNAs, such that the final con-
centration of siRNA was 30 nM for all targets. Cells were plated, and
media were changed the following morning. Three days after the initial
transfection, the cells were transfected a second time using HiPerFect/
siRNA concentrations, as described above. All siRNA treatments were
compared with the All-Stars Control siRNA (QIAGEN). The catalog numbers
and target sequences of siRNAs used throughout this article are as follows:
ARF6 (catalog number SI02757286) 59-CAACGTGGAGACGGTGAC-
TTA-39; MyD88 (catalog number SI00300909) 59-AACTGGAACAGACA-
AACTATC-39; and ARNO (catalog number SI00061299) 59-CACGCTGTT-
GGTAATCTTATT-39.
Peptide synthesis
Peptides were synthesized in the University of Utah DNA/Peptide Core
Facility, using a standard Fmoc synthesis protocol, on an ABI 433 syn-
thesizer (Life Technologies/Applied Biosystems, Carlsbad, CA). In each
cycle, a 3- or 4-fold excess of the Fmoc–amino acid was activated with
a mix of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexa-
fluorophosphate, Oxyma Pure (ethyl cyano(hydroxyimino)acetate), and
diisopropylethylamine (1:1:2). Fmoc was removed in each cycle with 20%
piperidine. In peptides with N-terminal myristoyl the last coupling was
myristic acid. The peptide was cleaved and deprotected in a 2-h treatment
with trifluoroacetic acid/water/triisopropylsilane (95:2.5:2.5), followed
by precipitation in diethyl ether. The crude peptides were purified by
reversed-phase chromatography using a Hamilton PRP-1 column (Sigma
Aldrich) for myristoylated peptides or a Higgins Proto 200 C18 column
(Higgins Analytical, Mountain View, CA) for peptides without myristoyl.
In either case, a gradient of water/acetonitrile containing 0.1% trifluoro-
acetic acid was used. The purest fractions of the eluate were combined,
lyophilized, redissolved in 0.1 M HCl, and lyophilized again. Final purity
was .95%, as measured by reversed-phase chromatography monitored
at 214 nm. Molecular mass was confirmed within 0.1 Da by MALDI
mass spectrometry. The sequences of the peptides used throughout this
article are as follows: MyrARF6 2–13: Myristoyl- GKVLSKIFGNKE;
MyrSCR 2–13: Myristoyl- GNFKVILKGKES; and ARF6 2–13:
GKVLSKIFGNKE.
Transwell permeability
Permeability assays were adapted from previous protocols (15–17).
Twenty-four–well Costar cell culture inserts (1.0 mm pore, 0.3 cm2 total
growth area), coated with 100 ml 15 mg/ml human fibronectin solution,
were seeded with 30,000 HMVEC-Ds/insert, for a total of 105 cells/cm2.
The media were replaced the following day, and the assay was performed
after a stable confluent monolayer was formed, 48–72 h after seeding. LPS
(100 ng/ml) or Mock was added to both apical and basolateral sides of the
cell culture insert chamber in phenol red–free media and allowed to
stimulate for 4 h. HRP was added at a final concentration of 1 mg/ml to the
apical side of the cell culture insert 3 h after stimulation and allowed to
leak for 1 h. Media from the lower chamber were collected, and HRP
concentration was assessed by the addition of 0.5 mM guaiacol and 0.6
mM H2O2. Spectrophotometric analysis of absorbance at 490 nm was used
to assess permeability. For assays in which FITC dextran was used as
a reporter, the same protocol was followed with two exceptions: the assay
was carried out in EGM-2MV, and fluorometric analysis of media in the
lower chamber was performed using a microplate fluorometer to assess
fluorophore concentration. Data are presented as mean 6 SEM of at least
three independent experiments and $12 individual replicates.
ARF6-activation assay
Primary HMVEC-Ds were treated with agonists and inhibitors, as described
in the figure legends. Cells were lysed and immunoprecipitated with GGA3-
conjugated agarose beads (Cell Biolabs; STA419). Immunoprecipitates
(GTP-bound ARF6) and whole-cell lysates (total ARF6) were analyzed via
Western blot with an anti-ARF6 Ab (1:1000; Millipore; 05-1149).
VE-cadherin internalization
Internalization assays were adapted from previous protocols (15, 17).
HMVEC-Ds were seeded on eight-well, glass-bottom chamber slides
coated with human fibronectin. Cells were incubated in dialyzed VE-
cadherin BV6 Ab solution (Millipore; MABT134) that was diluted in la-
beling buffer (EBM-2 [Lonza] + 3% fatty acid–free BSA + 20 mM
HEPES) at a concentration of 5 mg/ml for 1 h at 4˚C. Media were replaced
with EGM-2MV with 100 ng/ml LPS or vehicle to stimulate endocytosis
and 0.6 mM Primaquine (Sigma) to block recycling of vesicles back to the
plasma membrane. Cells were acid washed three times in HBSS (Invi-
trogen) + Ca + Mg + 3% fatty acid–free BSA + 50 mM glycine (pH 2.7) to
remove noninternalized Ab and then fixed in 4% paraformaldehyde for 10
min at room temperature. Fixative was washed away with HBSS, and cells
were permeabilized with 0.3% Triton in HBSS for 5 min, followed by
blocking in 5% nonfat milk + 10% normal donkey serum in HBSS for 1 h.
Detection of VE-cadherin was performed with Alexa Fluor 488–conju-
gated anti-mouse IgG (Invitrogen), and cells were mounted in Antifade
medium + 2 mg/ml DAPI. Five random fields/well were imaged on an
Olympus FV1000 confocal microscope at 6003 with three individual Z-
slices, 0.3 mm apart. To quantify the images, each cell with .10 vesicles
stained positive for VE-Cadherin was tallied and divided by the total
number of DAPI-stained nuclei in the field. To score the image, the total
number of cells with greater than 10 488 nm positive vesicles divided by
the total number of cells (DAPI-stained nuclei)/field of a collapsed Z-
projection was calculated. Statistics were performed, using two-way ANOVA,
in Prism software.
Colocalization with EEA1 was performed in the same manner, but the
rabbit early endosome Ag 1 (EEA1) primary Ab (Abcam) was added
immediately after the blocking step and incubated for 1 h at room tem-
perature.
Immunoprecipitation
The coding sequence of each functional domain of full length of MyD88
and ARNO was amplified from IMAGE cDNA clones by PCR and ligated
into pcDNA3.1 vector after enzyme digestion. The ARNO and func-
tional-domain constructs contained a Myc and His epitope, whereas MyD88
constructs contained an HA epitope. 293T cells were transfected with the
indicated MyD88 or ARNO constructs. Cells were lysed in ice-cold 50
mM Tris (pH 7.5), 750 mM MgCl2, 1% Nonidet P-40, and 10% glycerol
supplemented with protease and phosphatase inhibitors (Thermo;
1861282) and incubated with immobilized anti-HA high-affinity rat mAb
(clone 3F10) agarose beads (Roche; 11 815 016 001) for 60 min at 4˚C.
Complexes were washed three times with lysis buffer and analyzed via
Western blot.
Cytokine analysis
HMVEC-D supernatants were treated as described in the figure legends.
Cytokine expression was measured with Millipore Milliplex magnetic bead
assays, per the manufacturer’s instructions. To assess murine plasma TNF-a
concentrations, 3–4-mo-old mice that had been treated i.p. with 25 mg/kg
LPS and i.v. with 40 mmol/kg peptide or vehicle were anesthetized, and blood
was collected via terminal cardiac puncture in the presence of EDTA. Whole
blood was centrifuged, and the plasma was obtained and stored at280˚C until
analysis. TNF-a concentrations were analyzed using the Mouse TNF-a
DuoSet ELISA (R&D Systems; DY410).
Leukocyte rolling and adherence assay
The protocol was adapted from previous studies (18, 19). HMVEC-Ds were
seeded into each well of a human fibronectin–coated parallel plate flow
chamber (U-plate 0.4 VI Fibronectin; Ibidi) at a density of 3 3 104 cells/
chamber. Media were changed daily until the cells had grown to conflu-
ence.
Human polymorphonuclear leukocytes (PMNs) were isolated using
previously described protocols (20, 21). Human peripheral venous blood
was collected from healthy, medication-free adult subjects and drawn into
acid-citrate-dextrose (14% final concentration) through standard veni-
puncture technique and used immediately upon collection. All subjects
provided informed consent, and Institutional Review board approval was
received for blood collection at the University of Utah. Platelet-rich plasma
was removed upon centrifugation of whole blood at 150 3 g for 20 min at
room temperature. The remaining red/WBC mixture was resuspended back
to the original volume with 0.9% saline solution. Six percent dextran 70
was added to the cell mixture and left for 1 h. The leukocyte-rich super-
natant was removed and centrifuged at 400 3 g for 5 min at 4˚C. The su-
pernatant was discarded, and the pellet was resuspended in 0.2% NaCl
immediately followed with an equal part 1.6% NaCl. Cells were centrifuged
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at 400 3 g for 5 min at 4˚C. The pellet was resuspended in HBSS sup-
plemented with 1% human serum albumin (HBSS/A) and layered over an
equal volume of Ficoll-Paque Plus. The suspension was centrifuged at 4˚C
for 30 min at 400 3 g. The mononuclear leukocyte layer was removed,
followed by the RBC layer, HBSS/A layer, and Ficoll-Paque layer. The
remaining pellet containing $95% PMNs was washed with HBSS/A and
resuspended to 106 cells/ml in warm Ultrasaline.
Endothelial cells previously seeded into flow chambers were treated with
LPS (100 ng/ml) and/or SC-514 for 3 h in complete media. A syringe pump
(Harvard Apparatus) was used to propel isolated and unstimulated primary
human leukocytes through the parallel plate flow chambers (at 1 dyne3 cm21
[typical venous shear stress (22)]) in Ultrasaline. Differential interference
contrast microscopy images were taken one time per second for 30 s using
an Olympus inverted microscope and a 103 objective, which is sufficient
for visualizing a large number of endothelial cells. The imaged area was in
the center (in both length and width) of each well, a point confirmed by the
manufacturer using computational fluid dynamics to demonstrate the most
uniform flow characteristics. The total number of PMNs rolling and ad-
hered in all 30 images was quantified using MetaMorph software. Data
presented are a quantification of the cumulative number of cells observed
to be adhered or rolling on the endothelial monolayer in each image (total
leukocytes adhered/30 s) 6 SEM and are representative of one large field
of view in the center of the well from at least four independent replicates.
Statistics were calculated using ANOVA and the Dunnett multiple-comparison
post hoc test.
VE-cadherin area quantification
HMVEC-Ds were seeded on BD Falcon clear-bottom 96-well tissue culture
plates (catalog number 353219) at a density of 10,000 cells/well. Cells were
incubated with the indicated treatments for 5 h and then fixed with 4%
paraformaldehyde in PBS for 10 min. Cells were permeabilized with 0.5%
Triton-X 100 for 2 min, blocked with Odyssey Blocking Buffer (LI-COR
Biosciences) for 30 min at room temperature, and incubated with a mouse
monoclonal VE-Cadherin Ab (BD; 555661) overnight at 4˚C. Cells were
rinsed with PBS and incubated with Alexa Fluor 488 donkey anti-mouse
secondary Ab and Hoechst 33258 dye for 4 h at room temperature. Cells
were rinsed, and the ImageXpress Micro XLS (Molecular Devices) col-
lected nine nonoverlapping images at the center of each well with a 203
objective. The VE-cadherin area of each image was quantified with ImageJ
by batch thresholding all images from an individual experiment and
quantifying the number of pixels that were VE-cadherin+ within each
image. The VE-cadherin area was divided by the number of nuclei/image
and normalized to the Mock treatments. Data were compiled from three
independent experiments with three replicate wells/condition in each ex-
periment and are composed of nine images/well, for a total of 81 images/
condition.
Organ permeability
This assay was adapted from previously published protocols (1, 23, 24).
Male C57BL/6 mice, between 8 and 12 wk of age (The Jackson Labora-
tory) were anesthetized with ketamine and given 40 mmol/kg peptide,
followed by 40 mg/kg Evans Blue dye in saline delivered i.v. via retro-
orbital sinus injection. Anesthesia was reversed with 50 ml 500 mg/ml
Antisedan (atipamezole) administered s.c. Six hours later, mice were eu-
thanized via CO2 asphyxiation, and the mass of each organ was measured.
Organs were placed in 1 ml formamide for 72 h at 60˚C to elute the dye
from each organ. Organs were centrifuged, and Evans blue dye accumu-
lation was measured at 620 nm with 740 nm correction. Values were
compared with a standard curve to calculate the total amount of dye/g
(wet-weight) in each organ. All animal experiments were approved by
the Animal Care and Use Committee of the University of Utah under
protocol number 12-10002.
Endotoxemia survival
Eight- to twelve-week-old male C57BL/6 mice (The Jackson Laboratory),
given 40 mmol/kg peptide i.v. via retro-orbital sinus injection and 25 mg/kg of
LPS i.p., were monitored at least four times each day until all living mice
resumed normal behaviors. To reduce death as an end point, all mice
observed to be unresponsive to touch were euthanized immediately by CO2
asphyxiation.
Statistics
Unless otherwise noted, statistics and p values were calculated using one-
way ANOVA, with the appropriate post hoc test, in PRISM software
version 5.0f.
Results
TLRs induce vascular leak by activation of ARF6
To determine whether ARF6 is involved in TLR-mediated endo-
thelial permeability, we used a well-characterized endothelial cell,
FIGURE 1. LPS uses the MyD88–ARNO–ARF6 cascade to destabilize
endothelial barriers. (A) HMVEC-Ds were exposed to 100 ng/ml LPS, and
active, GTP-bound ARF6 was assessed by GGA3 immunoprecipitation assay
and compared with total ARF6 in the lysate. (B) Quantification of data in (A)
showing the geometric mean and 95% confidence interval; asterisks denote
statistically significant results for which the lower bound of the 95% confi-
dence interval for the normalized ratio does not cross 1 (the null value,
represented as a dashed line). (C) HMVEC-Ds treated with siRNAs directed
toward ARF6 or a nontargeting control RNA (siCTL) were assessed for their
ability to reduce the leak of an HRP reporter after treatment with 100 ng/ml
LPS. HMVEC-Ds were transfected with siRNAs targeting ARNO (D) or
MyD88 (E) and assessed for the flow of HRP across an endothelial monolayer
after exposure to 100 ng/ml LPS. One-way ANOVA, with Dunnett multiple-
comparison test, were used for statistical analysis. (F) Domain map of MyD88
and ARNO constructs. (G) Lysates from HEK 293T cells expressing ARNO-
Myc and the indicated MyD88-HA constructs were immunoprecipitated with
anti-Myc Abs and immunoblotted with anti-HA Abs. (H) Lysates from HEK
293T cells expressing MyD88-HA and the indicated ARNO-Myc constructs
were immunoprecipitated with anti-Myc Abs and immunoblotted with anti-
HA Abs. *p , 0.05, **p , 0.01, ***p , 0.001.
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found to be sufficient for ARNO’s interaction with MyD88
(Fig. 1G, 1H).
A MyD88–ARNO–ARF6–controlled permeability hypothesis
suggests that, like IL-1b, modulation of ARF6 may be indepen-
dent of LPS-induced changes in gene expression and that those
changes may be dispensable for LPS-induced permeability. In-
deed, siRNAs targeting ARF6 were unable to block LPS-induced
TNF-a expression in endothelial cells (Fig. 2A). Additionally,
blocking LPS-induced transcription factor NF-kB or IRF3 acti-
vation using SC-514 or BX-795, respectively, failed to inhibit
LPS-induced permeability, but it blocked other LPS-induced
responses, including leukocyte rolling and TNF-a and IL-6 ex-
pression (Fig. 2B–F) (33, 34).
LPS induces permeability through VE-cadherin disruption
ARF6 was implicated in the regulation of the internalization of the
adherens junction protein VE-cadherin, which suggests that the
LPS-mediated increase in endothelial permeability occurs in a
paracellular manner. To test this, we assessed the leak of 2-MDa
FITC-dextran, a reporter too large for transcellular transport across
endothelial monolayers (35). We observed enhanced movement of
the 2-MDa dextran across the monolayer upon LPS stimulation,
suggesting that LPS enhances paracellular leak across the endo-
thelium (Fig. 3A). LPS also induced VE-cadherin internalization,
as shown by the enhanced presence of VE-cadherin in endocytic
vesicles containing EEA1 (Fig. 3B–D). This internalization was
abolished upon treatment of endothelial cells with siRNA directed
against ARF6 mRNA, further supporting the hypothesis that LPS
mediates permeability through ARF6-mediated adherens junction
internalization (Fig. 3E, 3F).
Inhibition of ARF6 with its N terminus reduces vascular leak
Having established that activation of ARF6 plays a critical role in
the enhancement of endothelial permeability, we wanted to determine
whether deactivation of ARF6 would enhance endothelial barriers
and reduce leak. A property of the ARF family of GTPases is that
peptides constructed of their N termini are proposed to inhibit
ARF GDP–GTP exchange (36, 37). We synthesized a myristoylated
peptide composed of amino acids 2–13 of ARF6 (MyrARF6 2–13).
The ARF6 N-terminal peptide, but not scrambled (MyrSCR 2–13)
or nonmyristoylated (ARF6 2–13) controls, was sufficient to reduce
ARF6 activation in HMVEC-Ds (Fig. 4A, 4B).
Our model predicts that reduced ARF6 activation would result in
enhanced endothelial barrier function. The ARF6 N terminus, but
not nonmyristoylated or scrambled controls, reduced permeability
across an endothelial monolayer (Fig. 4C). This reduction in
permeability corresponded to an increase in VE-cadherin at cell
junctions (Fig. 4D, 4E). This ARF6 inhibitory function was also
active in vivo and prevented the leak of Evans Blue dye from the
blood into both the lungs and the kidneys (Fig. 4F, 4G). These data
suggest that the synthetic ARF6 N terminus may be useful as
a novel therapeutic to prevent pathologies resulting from excess
inflammatory vascular leak.
The synthetic N terminus of ARF6 enhances survival during
endotoxic shock
Sepsis is a condition characterized by immense vascular leak that
leads to tissue dysfunction, shock, and, eventually, death. We
sought to determine whether the stabilizing activity of the ARF6 N
terminus could enhance survival of mice in the endotoxemia model
of sepsis. Lethal doses of LPS were administered i.p. immediately
following i.v. injection of peptides. Mice were monitored at least
four times per day until they resumed normal grooming behaviors
for $24 h. After 48 h, only 20% of the mice treated with LPS plus
FIGURE 4. An N terminus ARF6 peptide inhibits ARF6 activation
and reduces vascular permeability. (A and B) HMVEC-Ds were exposed
to 25 mM of the myristoylated ARF6 2–13 peptide, nonmyristoylated
ARF6 2–13 peptide, scrambled myristoylated ARF6 2–13 peptide, or
vehicle, and lysates were assessed for the ratio of ARF6-GTP/total
ARF6 in the cell lysates. Data are geometric mean and 95% confidence
interval; asterisk denotes a statistically significant result in which the
upper bound of the 95% confidence interval for the normalized ratio
does not cross 1 (the null value, represented as a dashed line). HMVEC-
Ds were exposed to the indicated treatments and assessed for their
ability to inhibit leak of HRP (C) or increase VE-cadherin surface area
(D and E). Mice were administered 40 mmol/kg of the indicated pep-
tides i.v. with Evans Blue dye. Kidneys (F) and lungs (G) were removed
6 h postinjection. The concentration of dye in each tissue is shown.
Representative panels in (D) were selected after enhancement of con-
trast to 0.4% saturation of pixels. Scale bar, 30 mm. *p , 0.05, **p ,
0.01, ***p , 0.001, one-way ANOVA and Tukey multiple-comparison
test. ns, not significant.
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vehicle or a nonmyristoylated peptide were alive. However, 85%
of the mice treated with LPS plus ARF6 N-terminal peptide were
alive at 48 h, and .70% of the mice recovered completely
(Fig. 5A). Interestingly, peptide treatment enhanced survival but
did not significantly affect serum cytokine levels (Fig. 5B). The
observation that peptide treatment does not affect cytokine levels
provides further evidence that ARF6 pathway inhibition can
protect mice from the deleterious effects of inflammation while
allowing canonical inflammatory cascades to continue (Fig. 6).
Discussion
We defined a signaling cascade in endothelial cells by which LPSs
induce vascular leak. We also described a peptide inhibitor of this
pathway, MyrARF6 2–13, which stabilized the vasculature in both
in vitro and in vivo assays and enhanced survival in a mouse
model of endotoxic shock.
The endothelial cell monolayer is the critical barrier between
blood and the peripheral tissues. It regulates the migration of fluid,
nutrients, and cells from blood into the interstitial space. The in-
tegrity of this barrier is maintained by a balance of opposing cues that
regulate endothelial cell transcytosis and cell–cell junctions (38). For
example, homophilic interactions of VE-cadherin at the cell–cell
junction are enhanced upon stimulation by TIE2-dependent angio-
poietin signaling (39) and ROBO4-dependent SLIT signaling (1),
but they are disrupted after stimulation with destabilizing cues, such
as VEGF (17), IL-1b (15), or LPS, as described in this article. The
ability of the stabilizing receptor ROBO4 to prevent leak and
pathologic angiogenesis is dependent on its ability to recruit the
GTPase activating protein, GIT1, to inactivate ARF6 (40). Con-
versely, the ability of the inflammatory mediators LPS and IL-1b to
destabilize the vasculature is dependent on their ability to activate
ARF6 (15). These observations, combined with the data from this
study, place ARF6 at the nexus of multiple pathways that disrupt the
endothelium. ARF6 activation leads to an unstable, leaky vascula-
ture, whereas ARF6 inhibition leads to a stable, less permeable
vasculature. This tightly regulated balance of endothelial stability
is disrupted in conditions such as sepsis or pulmonary infections.
During these conditions, the inflammatory response induces in-
tractable vascular leak, hypovolemic shock, and/or acute respiratory
distress syndrome, all of which can precipitate death. By blocking
ARF6 with its N-terminal peptide and reducing vascular leak, we
were able to enhance the survival of mice in the endotoxemia model
of sepsis.
Our in vitro and in vivo data demonstrate that ARF6 regulates
permeability independent from downstream inflammatory gene
expression. Knockdown of ARF6 expression in endothelial cells,
using specific siRNAs and the systemic in vivo administration of the
ARF6 N-terminal peptide, did not block LPS-induced TNF-a se-
cretion. Thus far, all of the evidence in animal models, including the
current study, suggests that ARF6, although necessary for disease
pathology, does not regulate cytokine release (15). In contrast, it
was proposed that inhibition of ARF6 in fibroblasts, macrophages,
and dendritic cells decreases LPS-induced cytokine production by
preventing the association of MyD88 with TIRAP and TLR4 (41,
42). However, LTA-induced cytokine expression, which also re-
quires the association of MyD88 with TIRAP, was not affected by
ARF6 inhibition, suggesting a greater complexity in these TLR-
signaling pathways (42). Furthermore, ARF6 inhibition had no ef-
fect on LPS-induced cytokine expression in dendritic cells (43).
Therefore, the preponderance of in vitro evidence, as well as that
from all in vivo studies published to date, suggests that ARF6 in-
hibition does not block cytokine expression or release.
FIGURE 5. The synthetic ARF6 N-terminal peptide
enhances survival during endotoxemia. Mice were
anesthetized with ketamine and administered a lethal
dose (25 mg/kg) of LPS i.p. concurrently with 40 mmol/
kg the indicated peptide i.v. and monitored for survival
(A) and plasma TNF-a concentration after 5 h (n = 4
mice/group) (B). *p , 0.05, Mantel–Cox test (A) and
one-way ANOVA with Dunnett multiple-comparison
test (B). ns, not significant.
FIGURE 6. LPS uses a MyD88–ARNO–ARF6 cas-
cade to induce VE-cadherin internalization and vascu-
lar permeability independent from cytokine expression.
LPS stimulates TLR4, which recruits the adapter pro-
teins MyD88 and TRIF to facilitate downstream tran-
scriptional regulation, such as cytokine expression. LPS
also stimulates an independent and divergent pathway
through the MyD88–ARNO–ARF6–signaling axis that
dissociates VE-cadherin from the cell–cell junctions,
allowing for vascular leak to occur. MyrARF6 2–13
blocks this divergent pathway by deactivating ARF6
and reducing vascular leak.
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Aside from enhancing vascular stability, inhibition of a highly
conserved molecule, such as ARF6, may have a number of de-
velopmental effects. For example, genetic ablation of ARF6 leads
to the failure of proper hepatic cord formation and is embryonically
lethal (44). However, the specific ablation of ARF6 in adults has
not been described. In adult mice, inhibition of the ARF family of
GTPases prevented signal transduction of the insulin-receptor
complex, leading to transient insulin resistance (45). Addition-
ally, inhibition for 2 wk showed no obvious toxicity, but it de-
creased inflammatory pathologies in mouse models of arthritis
(15). ARF inhibition also reduced invasion and metastasis of
melanoma xenografts (31). Furthermore, ARF6 inhibition blocked
proper VEGF receptor signaling and angiogenesis (40, 46), as well
as altered platelet activation (36, 47). Determining the effects of
ARF6 inhibition on other tissues, especially in the context of
hyperinflammation and sepsis, is an important and ongoing area
of research in our laboratory and others.
This study identified a novel host–pathogen interaction through
which bacterial LPSs activate a MyD88–ARNO–ARF6 cascade
that induces endothelial leak independent of cytokine expression
after stimulation (Fig. 6). We characterize an ARF6 inhibitor that
reduces vascular leak and increases survival during lethal LPS-
induced endotoxemia. MyD88 is a central effector of innate im-
munity; blocking the MyD88–ARNO–ARF6 cascade might serve
to stabilize the vasculature and prevent pathologies induced by
multiple diverse inflammatory events, regardless of the stimulus.
We expect that this study will open new avenues for the devel-
opment of therapeutics that could be used for the treatment of
inflammatory processes related to infection, as well as any in-
flammatory process associated with vascular instability, including
trauma, epilepsy, and autoimmune diseases, such as multiple sclerosis
(48–50).
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Appendix: The N-terminus of ARF6 is an antimicrobial  
peptide with activity in vitro but not live animal assays. 
Introduction 
Thus far, Chapter 3 has demonstrated that a peptide composed of the amino 
terminus of ARF6 (MyrARF6 2-13) is a potent bioactive molecule that deactivates ARF6 
in the endothelium and enhances vascular stability.  However, the structure of MyrARF6 
2-13 suggests that it may have other functions as well.  MyrARF6 2-13 is a cationic, 
amphipathic helix 1, a trait possessed by a class of peptides functionally named 
“antimicrobial peptides 2,” or AMPs. The experiments outlined in this appendix 
characterize MyrARF6 2-13’s function as a putative AMP. Our data suggest that 
MyrARF6 2-13 interacts with LPS, prevents LPS-mediated cytokine production, and 
inhibits growth of a pathogenic strain of Escherichia coli in in vitro assays. However, 
when MyrARF6 2-13 is administered to mice, no such antimicrobial affect was observed, 
suggesting that its antimicrobial capabilities are limited to in vitro settings. 
AMPs are a subclass of membrane-active peptides (MAPs) utilized to bind cell-
wall components of bacteria and facilitate bacterial lysis. AMPs are similar to another 
subclass of MAPs known as cell-penetrating peptides used to deliver macromolecules 
into cells 2b. One structural domain present in both peptide subclasses is the amphipathic 
helix. The ARF6 amino terminus (Figure 3.1), the domain of ARF6 responsible for its 







Due to the structural similarly of the ARF6 N-terminus to antimicrobial peptides, 
we wanted to determine if MyrARF6 2-13 had antimicrobial peptide-like activity. We 
utilized a cadaverine displacement assay to detect an LPS interaction 4. BODIPY 
cadaverine binds to the lipid-A portion of LPS and the resulting hydrophobic 
environment limits the fluorescence of the BODIPY fluor. In the presence of LPS-
binding molecules such as Polymyxin B or antimicrobial peptides, the bodipy cadaverine 
is released and fluorescence is enhanced. Indeed, presence of both L- and D-enantiomers 
of MyrARF6 2-13, but not scrambled (MyrSCR 2-13) or non-myristoylated controls, 
were sufficient to enhance the fluorescence of bodipy cadaverine in the presence of LPS, 
suggesting that MyrARF6 2-13 can bind and interact with LPS and this interaction is 
chirality-independent. 
Having detected a potential interaction between MyrARF6 2-13 and LPS, we 
sought to determine if MyrARF6 2-13 could prevent LPS-induced signal transduction. 
Upon treatment with LPS, endothelial cells secrete cytokines into the culture media. If 
MyrARF6 2-13 prevents LPS-mediated signal transduction, we would expect a reduction 
in the total amount of cytokines released into the culture media. Indeed, both L- and D-
enantiomers of MyrARF6 2-13 were sufficient to block LPS-mediated IL-6 secretion, but 
not TNF-α-mediated IL-6 secretion (Figure 3.3).  
Many LPS-binding peptides not only prevent LPS-induced signaling cascades, but 
are bactericidal and prevent bacterial replication 2a.  Because of this, we wanted to 
determine if MyrARF6 2-13 was bactericidal. Indeed, both enantiomers of MyrARF6 2-
13 equally blocked the growth of E. coli, but not to the same potency as previously 
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described antimicrobial molecules: Temporin L and Polymyxin B (Table 3.1). 
Collectively, our data suggest that the N-terminus of ARF6 has antimicrobial activity and 
could be classified as an AMP.  
Having determined that both L- and D- enantiomers of MyrARF6 were equipotent 
antimicrobial peptides, it became necessary to determine the contribution of the peptide’s 
antimicrobial activity to the enhancement of survival during endotoxemia we observed in 
the published work, in figure 5 of J. Immun 16 May, 2014, 
doi:10.4049/jimmunol.1400309. We hypothesized that it would be unlikely for the D-
enantiomer of MyrARF6 2-13 have the same ability to deactivate endogenous ARF6 and 
enhance endothelial stability as the L-enantiomer. Although both enantiomers display 
equipotent antimicrobial activities, the D-enantiomer is unable to deactivate endothelial 
ARF6 or enhance endothelial barrier function to the same extent as the L-enantiomer 
(Figure 3.4). 
Having observed that L-MyrARF6 2-13 behaves as an antimicrobial peptide that 
also inhibits ARF6 signaling and enhances endothelial stability, and the D-enantiomer 
only has antimicrobial activity, we were able to use the D-enantiomer to experimentally 
control for the antimicrobial activity of the L-enantiomer during endotoxemia. We 
therefore assessed the survival of mice after treatment with lethal doses of LPS with L-
MyrARF6 2-13 or the ARF6 inhibitory activity negative D-MyrARF6 peptides. 
Interestingly, treatment with the D-enantiomer, while slightly slowing the rate of death of 
septic mice, had no effect on overall survival or serum TNF-α levels, suggesting that the 
antimicrobial peptide effect is limited to in vitro settings such as tissue culture and 




 We have provided evidence to suggest that a peptide composed of the amino 
terminus of ARF6, MyrARF6 2-13, interacts with LPS, and prevents LPS-induced signal 
transduction in a manner similar to antimicrobial peptides. The amino termini of ARF 
proteins are responsible for membrane association, so the observation that a peptide 
construct of this domain has bacterial membrane binding properties is somewhat 
unsurprising.  We have also provided evidence to suggest that the antimicrobial activity is 
limited to in vitro assays because there is no evidence of inhibition of LPS-induced serum 
TNF-α levels or death in our in vivo endotoxemia model. Our observations suggest that 
researchers need to take great care in utilizing amino terminal ARF peptides as tools to 
probe ARF function in biological systems. 
  Importantly, we believe that the data presented in this appendix could be used to 
explain two key observations about LPS in TLR4 signaling throughout the literature. An 
ARF6 amino-terminal peptide has been used to suggest that ARF6 activation is necessary 
for MYD88-Adapter-Like protein (MAL) to bridge MYD88 to TLR4 and facilitate LPS-
induced cytokine production 5. However, in these experiments, LPS was co-incubated 
with the peptide in tissue culture and the data are likely a consequence of a direct 
interaction that sequesters LPS rather than the TLR4 signaling cascade. Similar 
experimental methods were also utilized to suggest that ARF6 is necessary for TLR4-
Adapter-Protein (TRAM)-mediated TLR4 signaling 6. Supporting the conclusion that 
ARF6 is not involved in LPS-induced cytokine production is our observation that siRNAs 
directed again ARF6 fail to inhibit LPS-induced cytokine production in endothelial cells 
but are able to inhibit LPS-induced permeability. 
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Although we observed no antimicrobial affect of either the L- or the D-MyrARF6 
2-13 peptides in our endotoxemia assay, the treatments were administered in separate 
tissue compartments: LPS into the peritoneum, and the peptide intravenously. It is 
possible that if both were injected into the same tissue compartment then an antimicrobial 
affect may be observed. Collectively, the data presented in this appendix and throughout 
this dissertation suggests that two potential interactions between ARF6 and LPS exist: 
one of which is observed in vitro through a direct association with the N-terminus and 
LPS that prevents LPS-mediated signal transduction and another through MYD88 that 
facilitates LPS-induced VE-Cadherin internalization.  
 
Materials and methods 
Many of the experiments presented in this appendix were done concurrently or in 
a manner exactly the same as described in the methods as the manuscript printed earlier 
in this chapter. For siRNA, peptide synthesis, transwell permeability assay, ARF6 
activation, cytokine analysis, and endotoxemia survival assay methods, please refer to the 
Materials and Methods section on p43-45. 
Cadaverine displacement assay. This assay was adapted from previously 
published protocols 4. Briefly, serial dilutions of denoted treatments were incubated in 10 
µg/mL LPS and 1 µM bodipy cadaverine in 50 mM tris pH 7.4. Fluorescence was 
measured using a BioTek microplate fluorometer. 
Minimal inhibitory concentration (MIC) determination. Serial dilutions in 
Luria broth of denoted peptides were incubated over night at 37°C with a 1:10,000 
dilution of a stationary phase clinical isolate of E. coli.  The absorbance of the cultures 
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was assessed with a BioTek microplate spectrophotometer and the MIC was defined as 






















Figure 3.2 MyrARF6 interacts with LPS. LPS and BODIPY cadaverine were incubated 
with increasing concentrations of denoted treatments and fluorescence was measured 




Figure 3.3 MyrARF6 2-13 prevents LPS-induced, but not TNF-α-­‐induced cytokine 
expression. Endothelial cells were treated with (a) LPS or (b) TNF-α and denoted 
peptides. Supernatants were collected 5 hr post treatment and assessed for IL-6 
expression via Millipore Milliplex analysis.  
 
Table 3.1 MIC Table of MyrARF6 2-13. Denoted treatments were serially two-fold 
diluted in Luria broth and inoculated with 1:10,000 dilution of a clinical isolate of 
stationary phase E. coli. Bacteria were allowed to grow for 24 hr and the absorbance at 
OD 660 was assessed with a microplate reader. The lowest concentration of treatment 
that observed no difference in absorbance from media alone is reported in the table. NA = 
not applicable, used when bacteria grew at all tested concentrations. 
 




Figure 3.4 The L-, but not D- enantiomer MyrARF6 peptide blocks ARF6 activity 
and reduces endothelial permeability. (a-b) HMVEC-D were exposed to 25 µM 
treatments of the denoted peptides, or vehicle and lysates were assessed for the ratio of 
ARF6-GTP to total ARF6 in the cell lysate. Data are presented as the geometric mean 
and 95% confidence interval; asterisk denotes a statistically significant result in which the 
upper bound of the 95% confidence interval for the normalized ratio does not cross 1 (the 
null value). (c) HMVEC-D were exposed to the denoted treatments and assessed for their 




Figure 3.5 Antimicrobial peptide activity, but not ARF6-inhibiory activity is 
dispensable for MyrARF6 2-13 mediated survival during endotoxemia. Mice were 
anesthetized with ketamine and IP administered a lethal dose (25 mg/kg) of LPS 
concurrently with 40 mmol/kg-denoted peptide I.V. and monitored for survival (a) and 
plasma TNF-α concentration after 5 hr, n=4 mice per group (b). The Mantel-Cox test (a) 
and one-way ANOVA with Dunnett’s multiple comparisons tests (b) were used to assess 
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CHAPTER 4 
 
SUMMARY AND CONCLUSIONS 
 
Vascular leak is a phenomenon observed in nearly all inflammatory pathologies. The 
resulting improper fluid balance between the vessels and the peripheral tissues is associated 
with diminished tissue and organ function, damage, and in some cases, death. There are many 
pro-inflammatory cues and they vary widely in structure and source. Examples include small, 
host-produced, bio-active molecules such as histamine and bradykinins 1, inflammatory 
cytokines such as IL-1β and TNF-α 2, and danger-associated molecular patterns (DAMPs) 
such as bacterial lipopolysaccharides and chromosomal HMGB1 3, and others 4. These pro-
inflammatory cues all have specific receptors present in endothelial cells: GPCRs for 
histamine and bradykinins and single pass-enzyme linked receptors such as interleukin-1 
receptor for IL-1β and the TLRs for most DAMPs. This thesis described the identification of 
a pathway in host endothelial cells by which MYD88 recruits ARNO and ARF6 to induce 
permeability by destabilizing VE-cadherin at the cell junction.  
The characterization of ARF6 as a central mediator of vascular permeability in this 
dissertation was precipitated by the identification of ROBO4, a family member of the 
traditionally inhibitory axonal guidance receptors. Path-finding neurons structurally and 
behaviorally resemble angiogenic blood vessels and it was hypothesized that the stabilizing 
and inhibitory machinery described for neurons may be recycled for use in blood vessels. A 
screen was performed on mice that displayed enhanced endothelial instability and sprouting 
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defects to identify genes that resembled inhibitory receptors of neurons that were upregulated 
as a compensatory stabilizing mechanism 5. One such molecule is a member of the inhibitory 
neural guidance receptor family, the roundabouts, and was subsequently named Robo4. The 
roundabout family of proteins is canonically stimulated by their ligands, Slits. Stimulation of 
the Robo4 receptor on endothelial cells by the Slit2 protein prevented endothelial migration 
in a manner similar to Slit2’s effect on neurons. Slit2 also demonstrated Robo4-dependent 
inhibition of endothelial permeability 6. Further characterization of the downstream Robo4 
signaling pathway revealed that the cytoplasmic tail of Robo4 could interact with paxillin 7, a 
binding partner of the ARF6 GAP, GIT18. The ability of GIT1 to deactivate ARF6 upon Slit2 
stimulation was demonstrated to be necessary for Robo4’s stabilizing effects of the 
endothelium 7. We then asked if the converse was true, if Robo4 stabilizes the endothelium 
by deactivating ARF6, could it be possible that pro-inflammatory cues destabilize the 
endothelium by activating ARF6? Indeed, in Chapters 2 and 3, we showed that the 
destabilizing cues IL-1β and LPS activate ARF6 and that ARF6 activation is both necessary 
and sufficient to induce endothelial permeability. 
To determine how IL-1β and LPS activate ARF6, we interrogated their highly similar 
and well-characterized signaling pathways. Both of their receptors recruit MYD88 to 
facilitate an IL-1R-associated kinase (IRAK)-initiated signaling cascade culminating in the 
activation of Iκ B kinase complex (IKK) to phosphorylate Iκ B-α.  This allows NF-κB and 
other transcription factors to transport into the nucleus and facilitate the expression of 
inflammatory genes such as cytokines and cell adhesion molecules. However, inhibition of 
new transcription and translation did not block IL-1β-induced permeability, suggesting 
permeability and ARF6 activation occurred upstream of changes in gene expression. siRNAs 
directed against MYD88 but not IRAK blocked IL-1β-induced ARF6 activation, suggesting 
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that MYD88 may be acting as a scaffold for an ARF6 GEF. Immunoprecipitation revealed 
that MYD88 associated with ARNO, and that this MYD88-ARNO interaction facilitated 
ARF6 activation. 
We showed that a MYD88-ARNO-ARF6-cadherin signaling axis was responsible for 
enhancing endothelial permeability, but importantly, we also observed that this enhancement 
was independent of the other components of the inflammatory response such as expression of 
cytokines and cell adhesion molecules. The separation of pathology from the cytokine 
response is a unique observation because most of the proposed treatments for inflammatory 
diseases such as arthritis and sepsis include broad-spectrum anti-inflammatories that directly 
target cytokines or block their expression. Indeed, the presence of inflammatory cytokines 
correlates well with pathology and is often sufficient to induce vascular leak and pathology. 
However, what we have described is a novel mechanism by which presence of inflammatory 
cues can be separated from the pathogenesis. This allows for the development of treatments 
to focus on the branch of the immune signaling pathways responsible for vascular leak to 
avoid side effects associated with broad-spectrum anti-inflammatories. Our data also suggest 
that vascular leak itself, and not other ancillary components of the inflammatory response 
such as the presence of cytokines and inflammatory cells, is a driver of the pathogenesis in 
inflammatory diseases such as arthritis and endotoxemia. It is possible that the inhibition of 
this axis may also prevent pathology in other inflammatory diseases where substantial 
vascular leak has been observed such as trauma, epilepsy, and multiple sclerosis 9. Future 
experiments should be directed toward elucidating the role of the ARF6 pathway in these 
diseases where vascular leak is an integral part of the pathogenesis. 
While we have identified ARF6 as a key regulator of VE-cadherin deposition and 
vascular permeability, the components downstream of ARF6 that facilitate this response 
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remain unidentified and are an important area of study. There are a number of potential 
models for ARF6-mediated VE-Cadherin destabilization. ARF6 is reported to be a key driver 
of PIP2 synthesis through its activation of PIP5K 10. PIP2 is a commonly used second 
messenger and PIP2 synthesized by PIP5K has been shown to enhance adhesion strength of 
N-Cadherin in fibroblasts 11. It is possible a similar mechanism may occur between in 
endothelial cells. Another possibility is that ARF6 might modulate reactive oxygen species 
(ROS)-sensitive phosphatases. ARF6 is a key regulator of ROS in neutrophils and endothelial 
cells 12. ARF6-mediated ROS activity may target the catalytic cysteine residue on VE-PTP or 
other endothelial PTPs and prevent phosphatase activity, thereby disrupting the 
phosphorylation status and stability of VE-Cadherin 13. Finally, it has also been demonstrated 
that ARF6 GTP status is sufficient to induce positive membrane curvature 14. Therefore, 
ARF6 may be the component of the VE-cadherin endocytic machinery responsible for 
generation of the positive membrane curvature necessary to form the endocytic vesicle.  
One active area of study in our group is determining the extent to which the MYD88-
ARNO-ARF6-cadherin cascade is conserved among cell types. MYD88 is a widely 
expressed scaffolding protein present in epithelial cells, leukocytes, and many others 15. 
ARF6 is also expressed in many cell types 16. It is possible that such a cascade may have 
similar functions in other MYD88 expressing cells and preliminary data suggest ARF6 may 
regulate barrier function in epithelial cells. In a model of LPS-induced acute lung injury, 
administration of a small molecule inhibitor of ARNO/ARF6 signaling directly to the lung 
epithelium of mice blocked cellular infiltration and albumin flux into bronchial-alveolar 
lavage fluid (data not shown). However, it is not clear if this response is due to an effect of 
the small molecule interacting with the endothelium. Further experiments with lung alveolar 
epithelial cell-specific genetic knockouts of ARF6 are in progress to determine cell-
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specificity of this phenotype. Additionally, N-cadherin in leukocytes is important for 
attachment to endothelial cells, and blockade of this cascade may facilitate the enhancement 
of N-cadherin surface localization on leukocytes and increase attachment to endothelial cells. 
However, we detected no statistically significant changes in IL-1β-induced leukocyte 
attachment to endothelial cells 17 nor enhanced extravasation of leukocytes during 
endotoxemia (data not shown) upon ARF6 inhibition, suggesting that ARF6 may not be an 
important regulator of leukocyte adhesion. 
 Collectively, the observations contained within this dissertation have identified ARF6 
as a key regulator of vascular permeability that is independent of canonical inflammatory 
signaling leading to cytokine expression. They have also demonstrated a novel way to 
prevent inflammatory pathology: by reducing vascular leak. However, our observations have 
also raised many questions. What other cell types use this  axis and for what purposes? What 
are the downstream effectors of ARF6? What other diseases can be ameliorated by enhancing 
vascular stability? These questions are currently being investigated in our laboratory. Their 
answers will lead to novel insights into the mechanisms by which inflammation induces 
pathology, the biology of inflammatory cytokines, ARF6, cadherins, and vesicular 
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